<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T20:03:18Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:5167130" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:5167130</identifier><datestamp>2016-12-28</datestamp><setSpec>emmolmed</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">EMBO Mol Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">EMBO Mol Med</journal-id>
      <journal-id journal-id-type="doi">10.1002/(ISSN)1757-4684</journal-id>
      <journal-id journal-id-type="publisher-id">EMMM</journal-id>
      <journal-id journal-id-type="hwp">embomm</journal-id>
      <journal-title-group>
        <journal-title>EMBO Molecular Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1757-4676</issn>
      <issn pub-type="epub">1757-4684</issn>
      <publisher>
        <publisher-name>John Wiley and Sons Inc.</publisher-name>
        <publisher-loc>Hoboken</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5167130</article-id>
      <article-id pub-id-type="pmcid">PMC5167130</article-id>
      <article-id pub-id-type="pmc-uid">5167130</article-id>
      <article-id pub-id-type="pmid">27861123</article-id>
      <article-id pub-id-type="pmid">27861123</article-id>
      <article-id pub-id-type="doi">10.15252/emmm.201505719</article-id>
      <article-id pub-id-type="publisher-id">EMMM201505719</article-id>
      <article-categories>
        <subj-group subj-group-type="overline">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>Research Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>
<italic><styled-content style="fixed-case">TECRL</styled-content></italic>, a new lifeâthreatening inherited arrhythmia gene associated with overlapping clinical features of both <styled-content style="fixed-case">LQTS</styled-content> and <styled-content style="fixed-case">CPVT</styled-content>
</article-title>
        <alt-title alt-title-type="left-running-head">Harsha D Devalla <italic>etÂ al</italic></alt-title>
      </title-group>
      <contrib-group>
        <contrib id="emmm201505719-cr-0001" contrib-type="author" corresp="yes">
          <name>
            <surname>Devalla</surname>
            <given-names>Harsha D</given-names>
          </name>
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5343-1021</contrib-id>
          <address>
            <email>h.d.devalla@lumc.nl</email>
          </address>
          <xref ref-type="aff" rid="emmm201505719-aff-0001">
<sup>1</sup>
</xref>
          <xref ref-type="author-notes" rid="emmm201505719-note-1001">
<sup>â </sup>
</xref>
        </contrib>
        <contrib id="emmm201505719-cr-0002" contrib-type="author">
          <name>
            <surname>GÃ©linas</surname>
            <given-names>Roselle</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505719-aff-0002">
<sup>2</sup>
</xref>
          <xref ref-type="aff" rid="emmm201505719-aff-0003">
<sup>3</sup>
</xref>
          <xref ref-type="author-notes" rid="emmm201505719-note-1001">
<sup>â </sup>
</xref>
        </contrib>
        <contrib id="emmm201505719-cr-0003" contrib-type="author">
          <name>
            <surname>Aburawi</surname>
            <given-names>Elhadi H</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505719-aff-0004">
<sup>4</sup>
</xref>
          <xref ref-type="author-notes" rid="emmm201505719-note-1001">
<sup>â </sup>
</xref>
        </contrib>
        <contrib id="emmm201505719-cr-0004" contrib-type="author">
          <name>
            <surname>Beqqali</surname>
            <given-names>Abdelaziz</given-names>
          </name>
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1390-5821</contrib-id>
          <xref ref-type="aff" rid="emmm201505719-aff-0005">
<sup>5</sup>
</xref>
          <xref ref-type="author-notes" rid="emmm201505719-note-1001">
<sup>â </sup>
</xref>
        </contrib>
        <contrib id="emmm201505719-cr-0005" contrib-type="author">
          <name>
            <surname>Goyette</surname>
            <given-names>Philippe</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505719-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="emmm201505719-cr-0006" contrib-type="author">
          <name>
            <surname>Freund</surname>
            <given-names>Christian</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505719-aff-0001">
<sup>1</sup>
</xref>
          <xref ref-type="aff" rid="emmm201505719-aff-0006">
<sup>6</sup>
</xref>
        </contrib>
        <contrib id="emmm201505719-cr-0007" contrib-type="author">
          <name>
            <surname>Chaix</surname>
            <given-names>MarieâA</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505719-aff-0002">
<sup>2</sup>
</xref>
          <xref ref-type="aff" rid="emmm201505719-aff-0003">
<sup>3</sup>
</xref>
        </contrib>
        <contrib id="emmm201505719-cr-0008" contrib-type="author">
          <name>
            <surname>Tadros</surname>
            <given-names>Rafik</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505719-aff-0002">
<sup>2</sup>
</xref>
          <xref ref-type="aff" rid="emmm201505719-aff-0003">
<sup>3</sup>
</xref>
          <xref ref-type="aff" rid="emmm201505719-aff-0005">
<sup>5</sup>
</xref>
        </contrib>
        <contrib id="emmm201505719-cr-0009" contrib-type="author">
          <name>
            <surname>Jiang</surname>
            <given-names>Hui</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505719-aff-0007">
<sup>7</sup>
</xref>
          <xref ref-type="aff" rid="emmm201505719-aff-0008">
<sup>8</sup>
</xref>
          <xref ref-type="aff" rid="emmm201505719-aff-0009">
<sup>9</sup>
</xref>
        </contrib>
        <contrib id="emmm201505719-cr-0010" contrib-type="author">
          <name>
            <surname>Le BÃ©chec</surname>
            <given-names>Antony</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505719-aff-0010">
<sup>10</sup>
</xref>
        </contrib>
        <contrib id="emmm201505719-cr-0011" contrib-type="author">
          <name>
            <surname>MonshouwerâKloots</surname>
            <given-names>Jantine J</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505719-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="emmm201505719-cr-0012" contrib-type="author">
          <name>
            <surname>Zwetsloot</surname>
            <given-names>Tom</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505719-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="emmm201505719-cr-0013" contrib-type="author">
          <name>
            <surname>Kosmidis</surname>
            <given-names>Georgios</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505719-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="emmm201505719-cr-0014" contrib-type="author">
          <name>
            <surname>Latour</surname>
            <given-names>FrÃ©dÃ©ric</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505719-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="emmm201505719-cr-0015" contrib-type="author">
          <name>
            <surname>Alikashani</surname>
            <given-names>Azadeh</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505719-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="emmm201505719-cr-0016" contrib-type="author">
          <name>
            <surname>Hoekstra</surname>
            <given-names>Maaike</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505719-aff-0005">
<sup>5</sup>
</xref>
        </contrib>
        <contrib id="emmm201505719-cr-0017" contrib-type="author">
          <name>
            <surname>Schlaepfer</surname>
            <given-names>Jurg</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505719-aff-0011">
<sup>11</sup>
</xref>
        </contrib>
        <contrib id="emmm201505719-cr-0018" contrib-type="author">
          <name>
            <surname>Mummery</surname>
            <given-names>Christine L</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505719-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="emmm201505719-cr-0019" contrib-type="author">
          <name>
            <surname>Stevenson</surname>
            <given-names>Brian</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505719-aff-0010">
<sup>10</sup>
</xref>
        </contrib>
        <contrib id="emmm201505719-cr-0020" contrib-type="author">
          <name>
            <surname>Kutalik</surname>
            <given-names>Zoltan</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505719-aff-0010">
<sup>10</sup>
</xref>
          <xref ref-type="aff" rid="emmm201505719-aff-0012">
<sup>12</sup>
</xref>
        </contrib>
        <contrib id="emmm201505719-cr-0021" contrib-type="author">
          <name>
            <surname>de Vries</surname>
            <given-names>Antoine AF</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505719-aff-0013">
<sup>13</sup>
</xref>
          <xref ref-type="aff" rid="emmm201505719-aff-0014">
<sup>14</sup>
</xref>
        </contrib>
        <contrib id="emmm201505719-cr-0022" contrib-type="author">
          <name>
            <surname>Rivard</surname>
            <given-names>LÃ©na</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505719-aff-0002">
<sup>2</sup>
</xref>
          <xref ref-type="aff" rid="emmm201505719-aff-0003">
<sup>3</sup>
</xref>
        </contrib>
        <contrib id="emmm201505719-cr-0023" contrib-type="author">
          <name>
            <surname>Wilde</surname>
            <given-names>Arthur AM</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505719-aff-0015">
<sup>15</sup>
</xref>
          <xref ref-type="aff" rid="emmm201505719-aff-0016">
<sup>16</sup>
</xref>
        </contrib>
        <contrib id="emmm201505719-cr-0024" contrib-type="author">
          <name>
            <surname>Talajic</surname>
            <given-names>Mario</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505719-aff-0002">
<sup>2</sup>
</xref>
          <xref ref-type="aff" rid="emmm201505719-aff-0003">
<sup>3</sup>
</xref>
        </contrib>
        <contrib id="emmm201505719-cr-0025" contrib-type="author">
          <name>
            <surname>Verkerk</surname>
            <given-names>Arie O</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505719-aff-0005">
<sup>5</sup>
</xref>
          <xref ref-type="author-notes" rid="emmm201505719-note-1002">
<sup>â¡</sup>
</xref>
        </contrib>
        <contrib id="emmm201505719-cr-0026" contrib-type="author">
          <name>
            <surname>AlâGazali</surname>
            <given-names>Lihadh</given-names>
          </name>
          <xref ref-type="aff" rid="emmm201505719-aff-0004">
<sup>4</sup>
</xref>
          <xref ref-type="author-notes" rid="emmm201505719-note-1002">
<sup>â¡</sup>
</xref>
        </contrib>
        <contrib id="emmm201505719-cr-0027" contrib-type="author" corresp="yes">
          <name>
            <surname>Rioux</surname>
            <given-names>John D</given-names>
          </name>
          <address>
            <email>john.david.rioux@umontreal.ca</email>
          </address>
          <xref ref-type="aff" rid="emmm201505719-aff-0002">
<sup>2</sup>
</xref>
          <xref ref-type="aff" rid="emmm201505719-aff-0003">
<sup>3</sup>
</xref>
          <xref ref-type="author-notes" rid="emmm201505719-note-1001">
<sup>â </sup>
</xref>
          <xref ref-type="author-notes" rid="emmm201505719-note-1002">
<sup>â¡</sup>
</xref>
        </contrib>
        <contrib id="emmm201505719-cr-0028" contrib-type="author" corresp="yes">
          <name>
            <surname>Bhuiyan</surname>
            <given-names>Zahurul A</given-names>
          </name>
          <address>
            <email>z.a.bhuiyan@chuv.ch</email>
          </address>
          <xref ref-type="aff" rid="emmm201505719-aff-0017">
<sup>17</sup>
</xref>
          <xref ref-type="author-notes" rid="emmm201505719-note-1002">
<sup>â¡</sup>
</xref>
        </contrib>
        <contrib id="emmm201505719-cr-0029" contrib-type="author" corresp="yes">
          <name>
            <surname>Passier</surname>
            <given-names>Robert</given-names>
          </name>
          <address>
            <email>r.passier@lumc.nl</email>
          </address>
          <xref ref-type="aff" rid="emmm201505719-aff-0001">
<sup>1</sup>
</xref>
          <xref ref-type="aff" rid="emmm201505719-aff-0018">
<sup>18</sup>
</xref>
          <xref ref-type="author-notes" rid="emmm201505719-note-1002">
<sup>â¡</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="emmm201505719-aff-0001">
        <label>
          <sup>1</sup>
        </label>
        <named-content content-type="organisation-division">Department of Anatomy &amp; Embryology</named-content>
        <institution>Leiden University Medical Center</institution>
        <named-content content-type="city">Leiden</named-content>
        <country country="NL">The Netherlands</country>
      </aff>
      <aff id="emmm201505719-aff-0002">
        <label>
          <sup>2</sup>
        </label>
        <institution>Montreal Heart Institute</institution>
        <named-content content-type="city">Montreal</named-content>
        <named-content content-type="country-part">QC</named-content>
        <country country="CA">Canada</country>
      </aff>
      <aff id="emmm201505719-aff-0003">
        <label>
          <sup>3</sup>
        </label>
        <named-content content-type="organisation-division">Department of Medicine</named-content>
        <institution>UniversitÃ© de MontrÃ©al</institution>
        <named-content content-type="city">Montreal</named-content>
        <named-content content-type="country-part">QC</named-content>
        <country country="CA">Canada</country>
      </aff>
      <aff id="emmm201505719-aff-0004">
        <label>
          <sup>4</sup>
        </label>
        <named-content content-type="organisation-division">Department of Pediatrics</named-content>
        <named-content content-type="organisation-division">College of Medicine and Health Sciences</named-content>
        <institution>UAE University</institution>
        <named-content content-type="city">Al Ain</named-content>
        <country country="AE">United Arab Emirates</country>
      </aff>
      <aff id="emmm201505719-aff-0005">
        <label>
          <sup>5</sup>
        </label>
        <named-content content-type="organisation-division">Heart Failure Research Center</named-content>
        <named-content content-type="organisation-division">Academic Medical Center</named-content>
        <institution>University of Amsterdam</institution>
        <named-content content-type="city">Amsterdam</named-content>
        <country country="NL">The Netherlands</country>
      </aff>
      <aff id="emmm201505719-aff-0006">
        <label>
          <sup>6</sup>
        </label>
        <institution>Leiden University Medical Center hiPSC Core Facility</institution>
        <named-content content-type="city">Leiden</named-content>
        <country country="NL">The Netherlands</country>
      </aff>
      <aff id="emmm201505719-aff-0007">
        <label>
          <sup>7</sup>
        </label>
        <institution>Beijing Genomics Institute</institution>
        <named-content content-type="city">Shenzhen</named-content>
        <country country="CN">China</country>
      </aff>
      <aff id="emmm201505719-aff-0008">
        <label>
          <sup>8</sup>
        </label>
        <institution>Shenzhen Key Laboratory of Genomics</institution>
        <named-content content-type="city">Shenzhen</named-content>
        <country country="CN">China</country>
      </aff>
      <aff id="emmm201505719-aff-0009">
        <label>
          <sup>9</sup>
        </label>
        <institution>The Guangdong Enterprise Key Laboratory of Human Disease Genomics</institution>
        <named-content content-type="city">Shenzhen</named-content>
        <country country="CN">China</country>
      </aff>
      <aff id="emmm201505719-aff-0010">
        <label>
          <sup>10</sup>
        </label>
        <named-content content-type="organisation-division">VitalâIT group</named-content>
        <institution>Swiss Institute of Bioinformatics</institution>
        <named-content content-type="city">Lausanne</named-content>
        <country country="CH">Switzerland</country>
      </aff>
      <aff id="emmm201505719-aff-0011">
        <label>
          <sup>11</sup>
        </label>
        <named-content content-type="organisation-division">Service de Cardiologie</named-content>
        <institution>Centre Hospitalier Universitaire Vaudois (CHUV)</institution>
        <named-content content-type="city">Lausanne</named-content>
        <country country="CH">Switzerland</country>
      </aff>
      <aff id="emmm201505719-aff-0012">
        <label>
          <sup>12</sup>
        </label>
        <named-content content-type="organisation-division">Institute of Social and Preventive Medicine</named-content>
        <institution>University Hospital (CHUV) and University of Lausanne</institution>
        <named-content content-type="city">Lausanne</named-content>
        <country country="CH">Switzerland</country>
      </aff>
      <aff id="emmm201505719-aff-0013">
        <label>
          <sup>13</sup>
        </label>
        <named-content content-type="organisation-division">Laboratory of Experimental Cardiology</named-content>
        <named-content content-type="organisation-division">Department of Cardiology</named-content>
        <institution>Leiden University Medical Center</institution>
        <named-content content-type="city">Leiden</named-content>
        <country country="NL">The Netherlands</country>
      </aff>
      <aff id="emmm201505719-aff-0014">
        <label>
          <sup>14</sup>
        </label>
        <institution>ICINâNetherlands Heart Institute</institution>
        <named-content content-type="city">Utrecht</named-content>
        <country country="NL">The Netherlands</country>
      </aff>
      <aff id="emmm201505719-aff-0015">
        <label>
          <sup>15</sup>
        </label>
        <named-content content-type="organisation-division">Heart Center</named-content>
        <named-content content-type="organisation-division">Department of Clinical and Experimental Cardiology</named-content>
        <named-content content-type="organisation-division">Academic Medical Center</named-content>
        <institution>University of Amsterdam</institution>
        <named-content content-type="city">Amsterdam</named-content>
        <country country="NL">The Netherlands</country>
      </aff>
      <aff id="emmm201505719-aff-0016">
        <label>
          <sup>16</sup>
        </label>
        <institution>Princess AlâJawhara AlâBrahim Centre of Excellence in Research of Hereditary Disorders</institution>
        <named-content content-type="city">Jeddah</named-content>
        <country country="SA">Saudi Arabia</country>
      </aff>
      <aff id="emmm201505719-aff-0017">
        <label>
          <sup>17</sup>
        </label>
        <named-content content-type="organisation-division">Laboratoire GÃ©nÃ©tiquÃ© MolÃ©culaire</named-content>
        <institution>Centre Hospitalier Universitaire Vaudois (CHUV)</institution>
        <named-content content-type="city">Lausanne</named-content>
        <country country="CH">Switzerland</country>
      </aff>
      <aff id="emmm201505719-aff-0018">
        <label>
          <sup>18</sup>
        </label>
        <named-content content-type="organisation-division">Department of Applied Stem Cell Technologies</named-content>
        <named-content content-type="organisation-division">MIRA Institute for Biomedical Technology and Technical Medicine</named-content>
        <institution>University of Twente</institution>
        <named-content content-type="city">Enschede</named-content>
        <country country="NL">The Netherlands</country>
      </aff>
      <author-notes>
        <corresp id="correspondenceTo"><label>*</label>
Corresponding author. Tel: +31 715268889; Eâmail: <email>h.d.devalla@lumc.nl</email><break/>
Corresponding author. Tel: +1 5143763330 ext. 3741; Eâmail: <email>john.david.rioux@umontreal.ca</email><break/>
Corresponding author. Tel: +41 213143370; Eâmail: <email>z.a.bhuiyan@chuv.ch</email><break/>
Corresponding author. Tel: +31 534895553; Eâmail: <email>r.passier@lumc.nl</email><break/></corresp>
        <fn fn-type="equal" id="emmm201505719-note-1001">
          <label>â </label>
          <p>These authors contributed equally to this work</p>
        </fn>
        <fn fn-type="equal" id="emmm201505719-note-1002">
          <label>â¡</label>
          <p>These authors contributed equally to this work</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub">
        <day>24</day>
        <month>10</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>12</month>
        <year>2016</year>
      </pub-date>
      <volume>8</volume>
      <issue>12</issue>
      <issue-id pub-id-type="doi">10.1002/emmm.v8.12</issue-id>
      <fpage>1390</fpage>
      <lpage>1408</lpage>
      <history>
        <date date-type="received">
          <day>21</day>
          <month>8</month>
          <year>2015</year>
        </date>
        <date date-type="rev-recd">
          <day>20</day>
          <month>9</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>23</day>
          <month>9</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2016 EMBO <copyright-statement>-->
        <copyright-statement content-type="article-copyright">Â© 2016 The Authors. Published under the terms of the CC BY 4.0 license</copyright-statement>
        <license license-type="creativeCommonsBy">
          <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:type="simple" xlink:href="file:EMMM-8-1390.pdf"/>
      <abstract id="emmm201505719-abs-0001">
        <title>Abstract</title>
        <p>Genetic causes of many familial arrhythmia syndromes remain elusive. In this study, wholeâexome sequencing (<styled-content style="fixed-case">WES</styled-content>) was carried out on patients from three different families that presented with lifeâthreatening arrhythmias and high risk of sudden cardiac death (<styled-content style="fixed-case">SCD</styled-content>). Two French Canadian probands carried identical homozygous rare variant in <italic><styled-content style="fixed-case">TECRL</styled-content></italic> gene (p.Arg196Gln), which encodes the <italic>trans</italic>â2,3âenoylâCoA reductaseâlike protein. Both patients had cardiac arrest, stressâinduced atrial and ventricular tachycardia, and <styled-content style="fixed-case">QT</styled-content> prolongation on adrenergic stimulation. A third patient from a consanguineous Sudanese family diagnosed with catecholaminergic polymorphic ventricular tachycardia (<styled-content style="fixed-case">CPVT</styled-content>) had a homozygous splice site mutation (c.331+1G&gt;A) in <italic><styled-content style="fixed-case">TECRL</styled-content></italic>. Analysis of intracellular calcium ([Ca<sup>2+</sup>]<sub>i</sub>) dynamics in human induced pluripotent stem cellâderived cardiomyocytes (hi<styled-content style="fixed-case">PSC</styled-content>â<styled-content style="fixed-case">CM</styled-content>s) generated from this individual (<styled-content style="fixed-case">TECRL<sub>H</sub></styled-content>
<sub>om</sub>âhi<styled-content style="fixed-case">PSC</styled-content>s), his heterozygous but clinically asymptomatic father (<styled-content style="fixed-case">TECRL<sub>H</sub></styled-content>
<sub>et</sub>âhi<styled-content style="fixed-case">PSC</styled-content>s), and a healthy individual (<styled-content style="fixed-case">CTRL</styled-content>âhi<styled-content style="fixed-case">PSC</styled-content>s) from the same Sudanese family, revealed smaller [Ca<sup>2+</sup>]<sub>i</sub> transient amplitudes as well as elevated diastolic [Ca<sup>2+</sup>]<sub>i</sub> in <styled-content style="fixed-case">TECRL<sub>H</sub></styled-content>
<sub>om</sub>âhi<styled-content style="fixed-case">PSC</styled-content>â<styled-content style="fixed-case">CM</styled-content>s compared with <styled-content style="fixed-case">CTRL</styled-content>âhi<styled-content style="fixed-case">PSC</styled-content>â<styled-content style="fixed-case">CM</styled-content>s. The [Ca<sup>2+</sup>]<sub>i</sub> transient also rose markedly slower and contained lower sarcoplasmic reticulum (<styled-content style="fixed-case">SR</styled-content>) calcium stores, evidenced by the decreased magnitude of caffeineâinduced [Ca<sup>2+</sup>]<sub>i</sub> transients. In addition, the decay phase of the [Ca<sup>2+</sup>]<sub>i</sub> transient was slower in <styled-content style="fixed-case">TECRL<sub>H</sub></styled-content>
<sub>om</sub>âhi<styled-content style="fixed-case">PSC</styled-content>â<styled-content style="fixed-case">CM</styled-content>s due to decreased <styled-content style="fixed-case">SERCA</styled-content> and <styled-content style="fixed-case">NCX</styled-content> activities. Furthermore, <styled-content style="fixed-case">TECRL<sub>H</sub></styled-content>
<sub>om</sub>âhi<styled-content style="fixed-case">PSC</styled-content>â<styled-content style="fixed-case">CM</styled-content>s showed prolonged action potentials (<styled-content style="fixed-case">AP</styled-content>s) compared with <styled-content style="fixed-case">CTRL</styled-content>âhi<styled-content style="fixed-case">PSC</styled-content>â<styled-content style="fixed-case">CM</styled-content>s. <italic><styled-content style="fixed-case">TECRL</styled-content></italic> knockdown in control human embryonic stem cellâderived <styled-content style="fixed-case">CM</styled-content>s (<styled-content style="fixed-case">hESC</styled-content>â<styled-content style="fixed-case">CM</styled-content>s) also resulted in significantly longer <styled-content style="fixed-case">AP</styled-content>s. Moreover, stimulation by noradrenaline (<styled-content style="fixed-case">NA</styled-content>) significantly increased the propensity for triggered activity based on delayed afterdepolarizations (<styled-content style="fixed-case">DAD</styled-content>s) in <styled-content style="fixed-case">TECRL<sub>H</sub></styled-content>
<sub>om</sub>âhi<styled-content style="fixed-case">PSC</styled-content>â<styled-content style="fixed-case">CM</styled-content>s and treatment with flecainide, a class Ic antiarrhythmic drug, significantly reduced the triggered activity in these cells. In summary, we report that mutations in <italic><styled-content style="fixed-case">TECRL</styled-content></italic> are associated with inherited arrhythmias characterized by clinical features of both <styled-content style="fixed-case">LQTS</styled-content> and <styled-content style="fixed-case">CPVT</styled-content>. Patientâspecific hi<styled-content style="fixed-case">PSC</styled-content>â<styled-content style="fixed-case">CM</styled-content>s recapitulated salient features of the clinical phenotype and provide a platform for drug screening evidenced by initial identification of flecainide as a potential therapeutic. These findings have implications for diagnosis and treatment of inherited cardiac arrhythmias.</p>
      </abstract>
      <kwd-group kwd-group-type="author-generated">
        <kwd id="emmm201505719-kwd-0001">Arrhythmia</kwd>
        <kwd id="emmm201505719-kwd-0002">CPVT</kwd>
        <kwd id="emmm201505719-kwd-0003">iPSC</kwd>
        <kwd id="emmm201505719-kwd-0004">LQTS</kwd>
        <kwd id="emmm201505719-kwd-0005">SRD5A2L2</kwd>
      </kwd-group>
      <kwd-group kwd-group-type="subject-categories">
        <title>Subject Categories</title>
        <kwd>Cardiovascular System</kwd>
        <kwd>Genetics, Gene Therapy &amp; Genetic Disease</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>Netherlands Organization for Health Research and Development</funding-source>
          <award-id>ZonMwâTOP 40â00812â98â12086</award-id>
          <award-id>ZonMwâMKMDâ40â42600â98â036</award-id>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>European Research Council</funding-source>
          <award-id>STEMCARDIOVASCâ323182</award-id>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>Leenaards Foundation</funding-source>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>Swiss Institute of Bioinformatics</funding-source>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>Swiss National Science Foundation</funding-source>
          <award-id>31003Aâ143914</award-id>
          <award-id>51RTP0_151019</award-id>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>Fondation Suisse de Cardiologie</funding-source>
          <award-id>29283</award-id>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>Netherlands CardioVascular Research Initiative</funding-source>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>Dutch Federation of University Medical Centers</funding-source>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>Royal Netherlands Academy of Sciences</funding-source>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>Fondation de l'Institut de cardiologie de MontrÃ©al</funding-source>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>University of Montreal</funding-source>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>Hartstichting</funding-source>
        </award-group>
      </funding-group>
      <counts>
        <fig-count count="8"/>
        <table-count count="0"/>
        <page-count count="19"/>
        <word-count count="11226"/>
      </counts>
      <custom-meta-group>
        <custom-meta>
          <meta-name>source-schema-version-number</meta-name>
          <meta-value>2.0</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>component-id</meta-name>
          <meta-value>emmm201505719</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>December 2016</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>details-of-publishers-convertor</meta-name>
          <meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.0.0 mode:remove_FC converted:19.12.2016</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
    <notes>
      <p content-type="self-citation">
<mixed-citation publication-type="journal" id="emmm201505719-cit-1001">
<source>EMBO Mol Med</source> (<year>2016</year>) <volume>8</volume>: <fpage>1390</fpage>â<lpage>1408</lpage>
<pub-id pub-id-type="pmid">27861123</pub-id></mixed-citation>
</p>
    </notes>
    <notes>
      <p><related-article id="emmm201505719-note-8001" related-article-type="companion" xlink:href="10.15252/emmm.201606967" ext-link-type="doi"/>See also: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.15252/emmm.201606967">MD Perry &amp; JI Vandenberg</ext-link> (December 2016)</p>
    </notes>
  </front>
  <body>
    <sec id="emmm201505719-sec-0001">
      <title>Introduction</title>
      <p>Inherited arrhythmogenic diseases (IADs) are one of the prevalent causes of sudden cardiac death (SCD) in the young (Wilde &amp; Behr, <xref rid="emmm201505719-bib-0044" ref-type="ref">2013</xref>). IADs can be classified into disorders with or without structural heart defects. The latter include channelopathies such as long QT syndrome (LQTS) and catecholaminergic polymorphic ventricular tachycardia (CPVT), caused by mutations in genes encoding ion channel or calciumâhandling proteins that primarily affect the electrical activity of the heart (Schwartz <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0036" ref-type="ref">2013</xref>; Wilde &amp; Behr, <xref rid="emmm201505719-bib-0044" ref-type="ref">2013</xref>).</p>
      <p>LQTS is most commonly inherited in an autosomal dominant mode, where mutations in <italic>KCNH2</italic>,<italic> KCNQ1</italic>, and <italic>SCN5A</italic> account for the majority of cases (Wilde &amp; Behr, <xref rid="emmm201505719-bib-0044" ref-type="ref">2013</xref>). A very rare autosomal recessive form of LQTS, often accompanied with sensorineural deafness (JervellâLangeâNielsen syndrome), has been linked to mutations in <italic>KCNQ1</italic> and <italic>KCNE1</italic>. At least 12 other genes have been linked to LQTS. However, 20â30% of LQTS cases remain genetically elusive. The mechanism of arrhythmia in LQTS mainly involves QT prolongation with early afterdepolarizationâmediated triggered activity, whichÂ can lead to <italic>torsades de pointes</italic> (TdP) and ventricular fibrillation.</p>
      <p>CPVT is also commonly inherited as an autosomal dominant disorder due to mutations in the cardiac ryanodine receptor, <italic>RYR2</italic> (65% of all cases). Rare autosomal recessive mutations in the calciumâsequestering protein, <italic>CASQ2</italic> (2â5% of all cases), account for a small fraction of CPVT population (Lahat <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0021" ref-type="ref">2001</xref>; Laitinen <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0022" ref-type="ref">2001</xref>; Priori <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0032" ref-type="ref">2001</xref>; Postma <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0031" ref-type="ref">2002</xref>). Mutations in <italic>TRDN</italic> (RouxâBuisson <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0034" ref-type="ref">2012</xref>), a calcium release complex protein, and <italic>CALM1</italic> (Nyegaard <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0029" ref-type="ref">2012</xref>), a calciumâbinding protein, have also been implicated in CPVT. Interestingly, <italic>CALM1</italic>,<italic> CALM2,</italic> and <italic>CALM3</italic> mutations have also been linked to earlyâonset LQTS (Crotti <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0016" ref-type="ref">2013</xref>; Reed <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0033" ref-type="ref">2015</xref>; Chaix <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0014" ref-type="ref">2016</xref>), highlighting the locusâdisease heterogeneity in IADs. Clinically, a normal electrocardiogram (ECG) at rest and typical arrhythmias, including biâdirectional and polymorphic ventricular tachycardia (VT), in response to catecholaminergic stress isÂ observed in CPVT. Susceptibility to VT in response to Î²âadrenergic stimulation is the hallmark of CPVT, which manifests as exerciseâinduced syncope and sudden death (Leenhardt <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0023" ref-type="ref">2012</xref>).</p>
      <p>Although understanding of genetic loci associated with IADs has improved remarkably over the last few years, in a number of cases, the genetic basis of the clinical phenotype has remained elusive (Schwartz <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0036" ref-type="ref">2013</xref>). Genetic testing in LQTS and CPVT has been broadly adopted as a screening tool for these potentially fatal diseases. In cases without known diseaseâcausing mutations, identifying family members at risk of SCD can however be challenging. Therefore, discovering novel Mendelian diseaseâcausing loci through genetic testing has the potential to improve clinical care and prevent SCD.</p>
      <p>In this study, we identified mutations in <italic>trans</italic>â2,3âenoylâCoA reductaseâlike (<italic>TECRL</italic>) gene in three patients with clinical arrhythmias in whom none of the mutations in the most common LQTS and CPVT genes had been detected. Two of these patients were of French Canadian origin but unrelated and wereÂ diagnosed with LQTS at the Cardiovascular Genetics Center of the Montreal Heart Institute (MHI). They had strikingly similarÂ cardiac electrical phenotypes characterized by normal QT interval on their ECG at baseline, adrenergicâinduced QT prolongation as well as atrial and ventricular arrhythmias including aborted SCD. Wholeâexome sequencing (WES) of these patients revealed the presence of an identical homozygous rare variant in exon 6 of <italic>TECRL</italic>, also annotated <italic>SRD5A2L2</italic> (p.Arg196Gln).</p>
      <p>A third patient included in this study belongs to a consanguineous Arab family of Sudanese origin reported previously (Bhuiyan <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0008" ref-type="ref">2007</xref>). Members of this family were diagnosed with earlyâonset and highly malignant form of CPVT and segregation analysis indicated an autosomal recessive mode of inheritance. Sequencing of the coding exons and exonâintron boundaries of <italic>RYR2</italic> and <italic>CASQ2</italic> and several other cardiac genes such as <italic>KCNJ2</italic>,<italic> FKBP12.6</italic>,<italic> SCN5A</italic>,<italic> KCNH2</italic>,<italic> KCNQ1</italic>,<italic> KCNE1</italic>,<italic> KCNE2,</italic> and <italic>NCX1</italic> had not revealed any mutations. Here, we identified a homozygous G&gt;A point mutation in the splice donor site of intron 3 of <italic>TECRL</italic> (<italic>TECRL</italic>c.331+1G&gt;A) in the affected individuals of this family. To date, all but two children, who inherited this mutation in the affected family, died following a cardiac event during physical activity. To understand the functional consequence of the <italic>TECRL</italic>c.331+1G&gt;A mutation and model the disease phenotype <italic>inÂ vitro</italic>, we generated human induced pluripotent stem cells (hiPSCs) (Takahashi <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0038" ref-type="ref">2007</xref>) from a 5âyearâold symptomatic patient (referred to as TECRL<sub>Hom</sub>âhiPSCs), his heterozygous (but clinically asymptomatic) father (TECRL<sub>Het</sub>âhiPSCs), and a family member free of the mutation (CTRLâhiPSCs). hiPSCs were differentiated into cardiomyocytes (CMs) and analyzed <italic>inÂ vitro</italic>. Using the patientâderived hiPSCâCMs, we showed that the c.331+1G&gt;A mutation in <italic>TECRL</italic> leads to skipping of exon 3. TECRL<sub>Hom</sub>âhiPSCâCMs recapitulated aspects of the disease phenotype <italic>inÂ vitro</italic> including increased susceptibility to triggered activity, which could be alleviated by treatment with flecainide.</p>
      <p>Taken together, the clinical, genetic, and experimental results from this study have identified <italic>TECRL</italic> as a new gene associated with lifeâthreatening inherited arrhythmias displaying features of both LQTS and CPVT.</p>
    </sec>
    <sec id="emmm201505719-sec-0002">
      <title>Results</title>
      <sec id="emmm201505719-sec-0003">
        <title>Clinical data</title>
        <p>This study reports three patients from three different families presenting clinically with lifeâthreatening arrhythmias and cardiac arrest followed by successful resuscitation. Two of these patients were diagnosed with LQTS at the Cardiovascular Genetics Center of the Montreal Heart Institute following investigation for aborted cardiac arrest. They had distinctive clinical features of recurrent exerciseâ and emotionâinduced atrial and ventricular arrhythmias. The third patient was from a large consanguineous family with two subâfamilies and several children affected with adrenergicârelated lethal events and were previously diagnosed with CPVT (Bhuiyan <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0008" ref-type="ref">2007</xref>). Detailed clinical manifestations of these three patients and additional family members are described below and in the <xref rid="emmm201505719-sup-0001" ref-type="supplementary-material">Appendix</xref>.</p>
        <p>Patient 1 is a French Canadian female, who presented with ventricular fibrillation and cardiac arrest during walking at age 22, without prior history of syncope or documented arrhythmia. Coronary angiography, transthoracic echocardiography, and invasive electrophysiological (EP) testing, including ventricular premature stimulation, were normal. The resting ECG showed a normal QT interval, but isoproterenol infusion resulted in QT prolongation. During followâup, the patient presented with recurrent episodes of exerciseâ or emotionâinduced atrial and ventricular arrhythmias resulting in multiple shocks from an implantable cardioverterâdefibrillator (ICD). Arrhythmia was refractory to standard betaâblockers (metoprolol and bisoprolol) but was finally suppressed by high doses of nadolol. During further followâup, repeat echocardiography remained normal but significant repolarization abnormalities with QT prolongation (QTc range: 451â494Â ms) during followâup were occasionally seen on the resting ECG (FigÂ <xref rid="emmm201505719-fig-0001" ref-type="fig">1</xref>A); the patient was therefore diagnosed with LQTS. The parents were not known to be consanguineous but came from the same town. No family member was available for genetic testing.</p>
        <fig fig-type="Figure" xml:lang="en" id="emmm201505719-fig-0001" orientation="portrait" position="float">
          <label>Figure 1</label>
          <caption>
            <title>Arrhythmias in three different patients</title>
            <p>
<list list-type="alpha-upper" id="emmm201505719-list-0002"><list-item><p>12âlead ECG of patient 1.</p></list-item><list-item><p>12âlead ECG of patient 2.</p></list-item><list-item><p>ECG of patient 2 during epinephrine test [A, baseline ECG; B, ECG at 17Â min and 47Â s, at the beginning of epinephrine infusion (0.2Â Î¼g/kg of epinephrine); C, ECG after the end of epinephrine infusion].</p></list-item><list-item><p>Pedigree of a family diagnosed with arrhythmias; arrow indicates the proband, and solid symbols represent family members affected by arrhythmias who are also homozygous for mutations identified by exome sequencing. Crossed symbols indicate deceased individuals. Halfâfilled symbols correspond to individuals heterozygous for mutations identified by exome sequencing.</p></list-item><list-item><p>ECG of patient 3 (subject IV:13) showing mild QTc prolongation.</p></list-item><list-item><p>ICD interrogation of patient 3 (subject IV:13) reveals an episode of VT.</p></list-item></list>
</p>
          </caption>
          <graphic id="nlm-graphic-5" xlink:href="EMMM-8-1390-g002"/>
        </fig>
        <p>Patient 2 is also a French Canadian female. She presented initially at age 18 with numerous syncopal episodes triggered by emotional stress, with documentation of nonâsustained VT during exercise stress testing. Despite betaâblocker therapy, she had an aborted cardiac arrest during emotional stress at the age of 31. At rest, the QTc was 437Â ms with repolarization abnormalities (FigÂ <xref rid="emmm201505719-fig-0001" ref-type="fig">1</xref>B). Coronary angiography and cardiac magnetic resonance imaging were unremarkable. Sustained polymorphic VT was inducible with one ventricular extrastimulus during isoproterenol infusion. Epinephrine challenge resulted in a 57Â ms paradoxical QT prolongation with appearance of ventricular bigeminy, suggesting a low repolarization reserve compatible with LQTS (FigÂ <xref rid="emmm201505719-fig-0001" ref-type="fig">1</xref>C). During followâup, the patient had multiple episodes of adrenergic atrial and ventricular arrhythmia resulting in numerous ICD shocks. Electrophysiological mapping showed an extensive lowâvoltage area along the interatrial septum and multiple foci of atrial tachycardia (AT) was ablated. The combination of AT ablation and nadolol significantly decreased arrhythmia recurrence in this patient.</p>
        <p>Patient 3 (Subject 1V:13 of FigÂ <xref rid="emmm201505719-fig-0001" ref-type="fig">1</xref>D) is a Sudanese male who presented with cardiac arrest at age 4 while running. ECG recording during successful resuscitation showed ventricular fibrillation and TdP, which was reversed to sinus rhythm following DC shock. ECG showed a QTc interval of 450Â ms (FigÂ <xref rid="emmm201505719-fig-0001" ref-type="fig">1</xref>E). He had a second attack while in hospital but was in sinus rhythm between the two attacks with a normal QRS axis, aQTc interval of 450Â ms, and no ST changes. He later received an ICD and has had no further syncope or cardiac arrest. However, ICD interrogation occasionally revealed a fast rhythm around 193Â beats/min (cycle length 310Â ms) with polymorphic ventricular ectopy (FigÂ <xref rid="emmm201505719-fig-0001" ref-type="fig">1</xref>F). The parents of patient 3 are firstâdegree cousins and seven of 13 children in the family presented exertionâinduced arrhythmias and/or SCD during early childhood. In five of these children, an arrhythmic episode was fatal. Two children (IV:9 and IV:13) survived an arrhythmic attack. Clinical features of the other affected subjects are summarized in <xref rid="emmm201505719-sup-0001" ref-type="supplementary-material">AppendixÂ TableÂ S1</xref>. IV:1, IV:2, IV:4, and IV:10 have been described earlier (Bhuiyan <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0008" ref-type="ref">2007</xref>). Clinical details of IV:8, IV:9, and IV:13 are further detailed in the <xref rid="emmm201505719-sup-0001" ref-type="supplementary-material">Appendix</xref>.</p>
        <p>In summary, the clinical phenotype of the affected individuals is characterized by: (i) adrenergic VTs with high prevalence of cardiac arrest and SCD, (ii) recurrent AT sometimes triggering ventricular arrhythmias, and (iii) normal or mildly prolonged QTc at baseline with paradoxical QT increase during adrenergic stimulation. Taken together, the patients from all three families presented a similar severe arrhythmia phenotype with overlapping features of both LQTS and CPVT.</p>
      </sec>
      <sec id="emmm201505719-sec-0004">
        <title>WES revealed mutations in <italic>TECRL</italic> in all three patients</title>
        <p>To uncover the underlying genetic cause of arrhythmias in these patients, WES was performed on genomic DNA from patients and family members when available. Given the low prevalence of IADs, the fact that LQTS or CPVT can independently be caused by many different genes, and reasoning that most mutations identified to date are nonâsynonymous and familial in nature, we elected to focus our analyses exclusively on novel nonâsynonymous variants.</p>
        <sec id="emmm201505719-sec-0005">
          <title>WES revealed an identical homozygous missense mutation in TECRL in the French Canadian patients</title>
          <p>Patient 1 and patient 2 underwent clinical genetic testing and did not contain mutations in <italic>KCNQ1, KCNH2, SCN5A, KCNE1,</italic> or <italic>KCNE2,</italic> five genes most frequently implicated in LQTS. Overall, WES identified 57,828 highâquality single nucleotide variants (SNVs) and in/dels for these two subjects, 231 of which were novel nonâsynonymous coding and splice site variants. Given the striking similarity in disease phenotype, patient 1 and patient 2 were screened for variants in the same gene, which resulted in the identification of an identical novel homozygous single base pair (bp) mutation in <italic>TECRL,</italic> resulting in an arginine to glutamine substitution at position 196 (p.Arg196Gln). We developed a genotyping assay and confirmed independently that the mutation was homozygous in the two patients and absent in 540 Europeanâderived chromosomes. The p.Arg196Gln substitution is predicted to be âprobably damagingâ by PolyPhenâ2, deleterious by SIFT, and is within a site with a high Genomic Evolutionary Rate Profiling (GERP) score (5.11).</p>
        </sec>
        <sec id="emmm201505719-sec-0006">
          <title>WES revealed a common homozygous splice site mutation in TECRL in the affected members of the Sudanese family</title>
          <p>The pedigree of the Sudanese family (FigÂ <xref rid="emmm201505719-fig-0001" ref-type="fig">1</xref>D) was compatible with autosomal recessive inheritance. To reveal the underlying genetic cause of SCD, WES was performed on genomic DNA from two children, IV:2 and IV:10, who are firstâdegree cousins (FigÂ <xref rid="emmm201505719-fig-0001" ref-type="fig">1</xref>D) with clinical symptoms. Genomic DNA from the parents of IV:2 (III:1 and III:2; FigÂ <xref rid="emmm201505719-fig-0001" ref-type="fig">1</xref>D), who are clinically normal, was also included for WES. On average, this yielded â¥Â 81.5Â million reads per sample, 87% of which could be mapped. The mean coverage of the target region was &lt;Â 103âfold, with over 93% of target regions covered by â¥Â 10 reads. In total 67,000â78,000 SNVs and 4,300â5,400Â small in/dels were identified in each of the individuals, of which 1,401â1,789 were novel nonâsynonymous coding and splice site variants.</p>
          <p>We then prioritized variants according to disease inheritance pattern in the index patient, his parents, and affected cousin. This resulted in identification of five SNVs (<xref rid="emmm201505719-sup-0001" ref-type="supplementary-material">AppendixÂ TableÂ S2</xref>), all shared by IV:2 and IV:10 as homozygous and III:1 and III:2 as heterozygous following expected disease inheritance pattern. All these variants were further tested in the family members by Sanger sequencing. Of these, a single bp mutation in <italic>ANKRD17</italic> (p.Val1368Gly) and a splice site mutation in <italic>TECRL</italic> (c.331+1G&gt;A) were found to be homozygous in all children who had presented with a clinical phenotype (IV:2, IV:4, IV:8, IV:9, IV:10, and IV:13; FigÂ <xref rid="emmm201505719-fig-0001" ref-type="fig">1</xref>D) while the parents (III:1, III:2, III:3, and III:4) were found to be heterozygous in both families. <italic>ANKRD17</italic>c.4103T&gt;G and <italic>TECRL</italic>c.331+1G&gt;A variants were not reported as single nucleotide polymorphisms (SNPs) in the general population (neither in dbSNP, 1000 Genomes, 6500 NHLBI, ExAC browser nor in our inâhouse CoLaus and VitalâIT/SIB databases) and indicated a substitution deficit and evolutionary conservation (phastConsâ46 way score of 0.498 and GERP<sup>++</sup> score of 5.32 for <italic>ANKRD17</italic>; phastConsâ46 way score of 0.397 and GERP<sup>++</sup> score of 5.23 for <italic>TECRL</italic>). Additionally, these mutations were not found in any of control DNA samples obtained from 72 Saudi Arabian individuals. Importantly, no <italic>ANKRD17</italic> variant was identified in the two French Canadian patients.</p>
          <p>Taken together, the results from the French Canadian and Sudanese patients suggested that mutations in <italic>TECRL</italic> are the most likely cause of their lifeâthreatening arrhythmia.</p>
        </sec>
      </sec>
      <sec id="emmm201505719-sec-0007">
        <title>
<italic>TECRL</italic> is an endoplasmic reticulum (ER) protein expressed preferentially in the heart</title>
        <p>Human <italic>TECRL</italic> maps to chromosome 4q13 and contains 12 exons (<xref rid="emmm201505719-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S1A</xref>). The open reading frame of <italic>TECRL</italic> encodes a 363 amino acid protein and predicted to contain a ubiquitinâlike domain in the Nâterminal half of the protein, three transmembrane segments as well as a 3âoxoâ5âalpha steroid 4âdehydrogenase domain in the Câterminal half of the protein (<xref rid="emmm201505719-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S1B</xref> and <xref rid="emmm201505719-sup-0001" ref-type="supplementary-material">C</xref>). The homozygous mutation in <italic>TECRL</italic> found in patients 1 and 2 (p.Arg196Gln), is located in 6th exon of <italic>TECRL,</italic> and causes an amino acid substitution immediately upstream of the 3âoxoâ5âalphasteroid 4âdehydrogenase domain (<xref rid="emmm201505719-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S1C</xref>). On the other hand, <italic>TECRL</italic>c.331+1G&gt;A mutation found in patient 3 is located in the splice donor site of intron 3 resulting in an internal deletion in the putative ubiquitinâlike domain (<xref rid="emmm201505719-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S1AâC</xref>). Comparison of amino acid sequences of <italic>TECRL</italic> revealed a high degree of crossâspecies conservation (<xref rid="emmm201505719-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S1D</xref>), suggesting that <italic>TECRL</italic> might have an essential function in the heart.</p>
        <p>Previously, <italic>TECRL</italic> was identified in a genomeâwide transcriptional profiling study of human embryonic stem cells (hESCs) differentiating to CMs <italic>inÂ vitro</italic>. Moreover, in the mouse embryo, its expression was restricted to the heart and inflow tract (Beqqali <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0005" ref-type="ref">2006</xref>). To further define the spatiotemporal expression pattern of <italic>Tecrl</italic> during embryonic development, its expression in early mouse embryos was investigated by <italic>inÂ situ</italic> hybridization. <italic>Tecrl</italic> was not expressed in the cardiac crescent at embryonic day E7.5 (FigÂ <xref rid="emmm201505719-fig-0002" ref-type="fig">2</xref>A) but was observed at E8.5 in the entire heart with the strongest expression occurring in the developing inflow tract (FigÂ <xref rid="emmm201505719-fig-0002" ref-type="fig">2</xref>B), especially in the left horn (FigÂ <xref rid="emmm201505719-fig-0002" ref-type="fig">2</xref>C). At E9.5, <italic>Tecrl</italic> expression was still detectable in the atria and ventricles, albeit at lower levels whereas strong expression remained in the inflow tract (FigÂ <xref rid="emmm201505719-fig-0002" ref-type="fig">2</xref>D). From E10 onwards, <italic>Tecrl</italic> was also expressed at low levels in somites, particularly in the myotome region, that gives rise to skeletal muscle (FigÂ <xref rid="emmm201505719-fig-0002" ref-type="fig">2</xref>EâF). At E10.5, cardiac expression of <italic>Tecrl</italic> was no longer restricted to the inflow tract and its expression was maintained in the somites (FigÂ <xref rid="emmm201505719-fig-0002" ref-type="fig">2</xref>G). At E14.5, <italic>Tecrl</italic> was expressed in the entire myocardium but not in the lungs, which served as negative control (FigÂ <xref rid="emmm201505719-fig-0002" ref-type="fig">2</xref>H). In adult mice, reverse transcription quantitative polymerase chain reaction (RTâqPCR) analyses showed that <italic>Tecrl</italic> expression was highest in the heart with very low to almost undetectable levels in brain, skeletal muscle, stomach, pancreas, liver, kidney, small intestine, and uterus (<xref rid="emmm201505719-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S1E</xref>).</p>
        <fig fig-type="Figure" xml:lang="en" id="emmm201505719-fig-0002" orientation="portrait" position="float">
          <label>Figure 2</label>
          <caption>
            <title>Spatiotemporal, tissue, and subâcellular expression analysis of <italic><styled-content style="fixed-case">TECRL</styled-content></italic>
</title>
            <p>
<list list-type="simple" id="emmm201505719-list-0003"><list-item><label>AâH</label><p>Expression of <italic>Tecrl</italic> in mouse development. Expression is not observed in (A) the cardiac crescent at E7.5 but is prominent in (B) the inflow tract (ift) region at E8.5, particularly in (C) the left <italic>sinus venosus</italic> (lsv). (D) At E9.5, <italic>Tecrl</italic> expression is observed in all four chambers of the heart but is strongest in the inflow tract. (EâG) From E10 onwards, <italic>Tecrl</italic> is expressed in the somites. (H) At E14.5, <italic>Tecrl</italic> expression is present in the entire myocardium. Atrium (a), ventricle (v), myotome (m), neural tube (nt), lung (lu), right atrium (ra), left atrium (la), right ventricle (rv), and left ventricle (lv).</p></list-item><list-item><label>I</label><p>mRNA expression analyses of <italic>TECR</italic> and <italic>TECRL</italic> by RTâqPCR in human tissues demonstrate preferential expression of <italic>Tecrl</italic> in the heart. Bone marrow (Bone M.), heart, skeletal muscle (Sk.Muscle), uterus, liver, spleen, thymus, thyroid, prostate, brain, lung, small intestine (Small I.), and colon.</p></list-item><list-item><label>J</label><p>Localization of MYCâTecrl in COSâ1 cells. The accumulation of MYCâTecrl is perinuclear, consistent with it being localized to the ER. Scale bar: 10Â Î¼m.</p></list-item><list-item><label>KâM</label><p>Coâlocalization of MYCâTecrl and the ER marker calnexin in H10 cells. Nuclei stained with DAPI. Scale bar: 10Â Î¼m.</p></list-item></list>
</p>
          </caption>
          <graphic id="nlm-graphic-7" xlink:href="EMMM-8-1390-g003"/>
        </fig>
        <p>Next, we investigated the distribution of <italic>TECRL</italic> in human tissues. Interestingly, <italic>TECRL</italic> has important sequence identity with <italic>TECR</italic>, a gene that encodes a multiâpass membrane protein that resides in the ER, and belongs to the steroid 5âalpha reductase family (Moon &amp; Horton, <xref rid="emmm201505719-bib-0026" ref-type="ref">2003</xref>). Expression analysis of <italic>TECR</italic> and <italic>TECRL</italic> across a panel of human tissues clearly demonstrates that while <italic>TECR</italic> is ubiquitously expressed, <italic>TECRL</italic> is predominantly expressed in the heart and skeletal muscle (FigÂ <xref rid="emmm201505719-fig-0002" ref-type="fig">2</xref>I). Immunofluorescence analysis demonstrated that in COSâ1 cells, MYC epitopeâtagged mouse Tecrl protein primarily resides in the ER (FigÂ <xref rid="emmm201505719-fig-0002" ref-type="fig">2</xref>J), which was also confirmed in H10 cells by coâlocalization with calnexin, an ER chaperone (FigÂ <xref rid="emmm201505719-fig-0002" ref-type="fig">2</xref>KâM).</p>
        <p>Collectively, these results demonstrated that <italic>Tecrl</italic> encodes an ER protein expressed preferentially in the heart and that it is evolutionarily conserved, suggesting an important role in the heart.</p>
      </sec>
      <sec id="emmm201505719-sec-0008">
        <title>Derivation of patientâspecific hiPSCs and differentiation to CMs</title>
        <p>Skin biopsies were obtained from patient IV:13 carrying the homozygous <italic>TECRL</italic>c.331+1G&gt;A mutation, his heterozygous father, III:3, and a family member, IV:7 who does not carry the mutation.</p>
        <p>Dermal fibroblasts (FigÂ <xref rid="emmm201505719-fig-0003" ref-type="fig">3</xref>A; left image) were reprogrammed to hiPSCs with Sendai virus vectors encoding the four transcription factors OCT4, SOX2, KLF4, and MYC. Colonies obtained after reprogramming (FigÂ <xref rid="emmm201505719-fig-0003" ref-type="fig">3</xref>A; center image) morphologically resembled hESC colonies. hiPSC clones expressed the pluripotency markers, NANOG and SSEA4 (FigÂ <xref rid="emmm201505719-fig-0003" ref-type="fig">3</xref>A; right image; <xref rid="emmm201505719-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S2</xref>), and had a normal karyotype (FigÂ <xref rid="emmm201505719-fig-0003" ref-type="fig">3</xref>B; left image; <xref rid="emmm201505719-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S2</xref>). One line per genotype was selected for further experiments. The transcriptional profile of the hiPSC lines used in the study was analyzed by PluriTest (MÃ¼ller <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0027" ref-type="ref">2011</xref>), which showed a high pluripotency score and low novelty score as expected (FigÂ <xref rid="emmm201505719-fig-0003" ref-type="fig">3</xref>B; right image). The pluripotent nature of the hiPSCs was further confirmed by their ability to differentiate to derivatives of all three germ layers (FigÂ <xref rid="emmm201505719-fig-0003" ref-type="fig">3</xref>C). Importantly, nucleotide sequence analysis confirmed the presence of a homozygous c.331+1G&gt;A mutation in TECRL<sub>Hom</sub>âhiPSCs (FigÂ <xref rid="emmm201505719-fig-0003" ref-type="fig">3</xref>D).</p>
        <fig fig-type="Figure" xml:lang="en" id="emmm201505719-fig-0003" orientation="portrait" position="float">
          <label>Figure 3</label>
          <caption>
            <title>Generation of hi<styled-content style="fixed-case">PSC</styled-content>s and differentiation to cardiomyocytes</title>
            <p>
<list list-type="alpha-upper" id="emmm201505719-list-0004"><list-item><p>Skin fibroblasts (left) from IV:13, homozygous for the <italic>TECRL</italic>c.331+1G&gt;A mutation, were reprogrammed to hiPSCs (center), which expressed the pluripotency markers NANOG and SSEA4 (right). Scale bars: 100Â Î¼m.</p></list-item><list-item><p>TECRL<sub>Hom</sub>âhiPSCs have a normal karyotype (left) and PluriTest demonstrates a high pluripotency score and low novelty score for all three hiPSC lines (right).</p></list-item><list-item><p>TECRL<sub>Hom</sub>âhiPSCs generate derivatives of mesoderm (left), endoderm (center), and ectoderm (right). Scale bars: 25Â Î¼m.</p></list-item><list-item><p>DNA sequencing confirms <italic>TECRL</italic>c.331+1G&gt;A in the affected family members. Control (left); heterozygous (center); homozygous (right).</p></list-item><list-item><p>Schematic of the protocol used for cardiac differentiation of hiPSCs.</p></list-item><list-item><p>ACTN2 immunostaining of CTRLâ, TECRL<sub>Het</sub>â, and TECRL<sub>Hom</sub>âhiPSCâCMs. Scale bar: 25Â Î¼m.</p></list-item><list-item><p>Analysis of RTâPCR products by gel electrophoresis. Amplification products of <italic>TECRL</italic> exons 2â4 from CTRLâ, TECRL<sub>Het</sub>â, and TECRL<sub>Hom</sub>âhiPSCâCMs (left) and coding sequence of <italic>TECRL</italic> from CTRLâ and TECRL<sub>Hom</sub>âhiPSCâCMs (right).</p></list-item></list>
</p>
            <p>
<named-content content-type="attribution">Source data are available online for this figure.</named-content>
</p>
          </caption>
          <graphic id="nlm-graphic-9" xlink:href="EMMM-8-1390-g004"/>
        </fig>
      </sec>
      <sec id="emmm201505719-sec-0009">
        <title>A mutation at the exon 3âintron 3 boundary of <italic>TECRL</italic> leads to exon 3 skipping</title>
        <p>hiPSCs were differentiated to the cardiac lineage with a monolayer protocol (FigÂ <xref rid="emmm201505719-fig-0003" ref-type="fig">3</xref>E), and all three lines produced similar percentages of CMs. Contractile areas were observed in culture at day 10 of differentiation. The structure and organization of sarcomeres in TECRL<sub>Hom</sub>âhiPSCâCMs, TECRL<sub>Het</sub>âhiPSCâCMs and CTRLâhiPSCâCMs was similar based on ACTN2 immunostaining (FigÂ <xref rid="emmm201505719-fig-0003" ref-type="fig">3</xref>F).</p>
        <p>To determine the effect of the c.331+1G&gt;A mutation in <italic>TECRL</italic>, cDNA was prepared from hiPSCâCMs and PCR analysis was performed with primers designed to target <italic>TECRL</italic> exons 2â4. A 171âbp product is expected if the mRNA of <italic>TECRL</italic> contains exon 3, whereas a 126âbp product should be present when exon 3 is missing. Analysis of the amplicons from TECRL<sub>Het</sub>âhiPSCâCMs clearly showed two transcripts, a longer product containing exon 3 and a shorter DNA fragment lacking exon 3 (FigÂ <xref rid="emmm201505719-fig-0003" ref-type="fig">3</xref>G; left image). As expected, CTRLâhiPSCâCMs exclusively yielded the longer PCR product corresponding to 171Â bp. On the contrary, PCR analysis of TECRL<sub>Hom</sub>âhiPSCâCMs revealed a single product of 126Â bp (FigÂ <xref rid="emmm201505719-fig-0003" ref-type="fig">3</xref>G; left image), indicating that the c.331+1G&gt;A mutation in the splice donor site of <italic>TECRL</italic> intron 3 causes complete skipping of exon 3. Amplification of the entire <italic>TECRL</italic> coding region showed a shorter PCR product (1,046Â bp) of <italic>TECRL</italic> from TECRL<sub>Hom</sub>âhiPSCâCMs compared to the 1,091âbp amplicon of CTRLâhiPSCâCMs (FigÂ <xref rid="emmm201505719-fig-0003" ref-type="fig">3</xref>G; right image). Nucleotide sequencing analysis of the PCR product from TECRL<sub>Hom</sub>âhiPSCâCMs confirmed deletion of 45Â bp corresponding to exon 3.</p>
      </sec>
      <sec id="emmm201505719-sec-0010">
        <title>TECRL<sub>Hom</sub>âhiPSCâCMs exhibit abnormalities in calcium handling</title>
        <p>Impaired calcium homeostasis underlies the pathophysiology of various IADs, particularly CPVT. To investigate whether the <italic>TECRL</italic>c.331+1G&gt;A mutation has an effect on canonical calciumâhandling proteins, we investigated their expression at the protein level by Western blotting. There was a 52% reduction in RYR2 protein and 85% reduction in CASQ2 protein in TECRL<sub>Hom</sub>âhiPSCâCMs, while SERCA2a, PLB, NCX, and Ca<sub>v</sub>1.2 protein levels were unaffected (<xref rid="emmm201505719-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S3</xref>).</p>
        <p>Next, we studied intracellular calcium ([Ca<sup>2+</sup>]<sub>i</sub>) transients of TECRL<sub>Hom</sub>âhiPSCâCMs. FigÂ <xref rid="emmm201505719-fig-0004" ref-type="fig">4</xref>A shows typical [Ca<sup>2+</sup>]<sub>i</sub> transient recordings of CTRLâhiPSCâCMs, TECRL<sub>Het</sub>âhiPSCâCMs, and TECRL<sub>Hom</sub>âhiPSCâCMs following 1âHz electrical stimulation. A summary of average [Ca<sup>2+</sup>]<sub>i</sub> characteristics is shown in FigÂ <xref rid="emmm201505719-fig-0004" ref-type="fig">4</xref>B and C. The [Ca<sup>2+</sup>]<sub>i</sub> transient rose markedly slower in TECRL<sub>Hom</sub>âhiPSCâCMs than in CTRLâhiPSCâCMs (FigÂ <xref rid="emmm201505719-fig-0004" ref-type="fig">4</xref>A) resulting in a significant difference in the time required to reach 50% of the [Ca<sup>2+</sup>]<sub>i</sub> transient amplitude, t<sub>1/2</sub> (FigÂ <xref rid="emmm201505719-fig-0004" ref-type="fig">4</xref>B). While there were no significant differences in systolic [Ca<sup>2+</sup>]<sub>i</sub>, the diastolic [Ca<sup>2+</sup>]<sub>i</sub> was markedly higher in TECRL<sub>Hom</sub>âhiPSCâCMs compared with CTRLâhiPSCâCMs (FigÂ <xref rid="emmm201505719-fig-0004" ref-type="fig">4</xref>B). Consequently, the amplitude of the [Ca<sup>2+</sup>]<sub>i</sub> transient was lower in TECRL<sub>Hom</sub>âhiPSCâCMs (FigÂ <xref rid="emmm201505719-fig-0004" ref-type="fig">4</xref>C). Furthermore, the decay of the [Ca<sup>2+</sup>]<sub>i</sub> transient was remarkably slower in TECRL<sub>Hom</sub>âhiPSCâCMs, as indicated by the significant increase in the time constant (tau) of decay (FigÂ <xref rid="emmm201505719-fig-0004" ref-type="fig">4</xref>C).</p>
        <fig fig-type="Figure" xml:lang="en" id="emmm201505719-fig-0004" orientation="portrait" position="float">
          <label>Figure 4</label>
          <caption>
            <title>Wholeâcell [Ca<sup>2+</sup>]<sub>i</sub> transients in hi<styled-content style="fixed-case">PSC</styled-content>â<styled-content style="fixed-case">CM</styled-content>s</title>
            <p>
<list list-type="alpha-upper" id="emmm201505719-list-0005"><list-item><p>Representative traces of [Ca<sup>2+</sup>]<sub>i</sub> transients in Indoâ1 AMâloaded hiPSCâCMs paced at 1Â Hz.</p></list-item><list-item><p>Time to reach 50% of [Ca<sup>2+</sup>]<sub>i</sub> transient amplitude (t<sub>1/2</sub>) and [Ca<sup>2+</sup>]<sub>i</sub> concentrations during systole and diastole.</p></list-item><list-item><p>Amplitude and tau decay of the [Ca<sup>2+</sup>]<sub>i</sub> transient.</p></list-item></list>Data information: <italic>nÂ </italic>=<italic>Â </italic>5â6 cells each from three independent experiments (meanÂ Â±Â SEM); *<italic>PÂ </italic>&lt;<italic>Â </italic>0.05, statistical significance was assessed with oneâway ANOVA on ranks followed by Dunn's test in case of failed normality or variance. Otherwise, oneâway ANOVA followed by StudentâNewmanâKeuls test was used.</p>
          </caption>
          <graphic id="nlm-graphic-11" xlink:href="EMMM-8-1390-g005"/>
        </fig>
        <p>To gain further insight into the observed differences in [Ca<sup>2+</sup>]<sub>i</sub> transient properties of TECRL<sub>Hom</sub>âhiPSCâCMs and ascertain the cause of slower decay time, we measured the activity of sarcoplasmic reticulum (SR) Ca<sup>2+</sup> ATPase (SERCA), Na<sup>+</sup>âCa<sup>2+</sup> exchanger (NCX), and the slow mechanisms (mitochondrial Ca<sup>2+</sup> uniporter and sarcolemmal Ca<sup>2+</sup> ATPase) in Ca<sup>2+</sup> extrusion from the cytoplasm by application of the RYR2 agonist, caffeine, and the NCX1 blocker, NiCl<sub>2</sub> (Bassani &amp; Bers, <xref rid="emmm201505719-bib-0004" ref-type="ref">1995</xref>; DÃ­az <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0018" ref-type="ref">2004</xref>). About 10Â mM caffeine induced fast release of Ca<sup>2+</sup> from the SR into the cytosol and SERCA activity (<italic>K</italic>
<sub>SERCA</sub>) was analyzed by comparing the rates of decay of spontaneous [Ca<sup>2+</sup>]<sub>i</sub> transients (<italic>K</italic>
<sub>sys</sub>) and caffeineâevoked transients (<italic>K</italic>
<sub>caff</sub>). The role of NCX in Ca<sup>2+</sup> removal from the cytoplasm was obtained through subtraction of the rate of decay ofÂ the caffeineâevoked [Ca<sup>2+</sup>]<sub>i</sub> transients (<italic>K</italic>
<sub>caff</sub>) from that of caffeineâevoked [Ca<sup>2+</sup>]<sub>i</sub> transients in the presence of 10Â mM NiCl<sub>2</sub> (<italic>K</italic>
<sub>Caff+Ni</sub>). Representative [Ca<sup>2+</sup>]<sub>i</sub> transients of a CTRLâhiPSCâCM and TECRL<sub>Hom</sub>âhiPSCâCM are shown in FigÂ <xref rid="emmm201505719-fig-0005" ref-type="fig">5</xref>A.</p>
        <fig fig-type="Figure" xml:lang="en" id="emmm201505719-fig-0005" orientation="portrait" position="float">
          <label>Figure 5</label>
          <caption>
            <title>[Ca<sup>2+</sup>]<sub>i</sub> extrusion mechanisms in hi<styled-content style="fixed-case">PSC</styled-content>â<styled-content style="fixed-case">CM</styled-content>s</title>
            <p>
<list list-type="alpha-upper" id="emmm201505719-list-0006"><list-item><p>Representative traces of [Ca<sup>2+</sup>]<sub>i</sub> transients in Indoâ1 AMâloaded hiPSCâCMs paced at 1Â Hz, in the presence of caffeine (caff) or caffeine and NiCl<sub>2</sub>.</p></list-item><list-item><p>Amplitude of [Ca<sup>2+</sup>]<sub>i</sub> in the presence of caffeine and NiCl<sub>2</sub> and fractional SR release in hiPSCâCMs.</p></list-item><list-item><p>Rate constants of SERCAâ, NCXâ, and slow mechanismâbased [Ca<sup>2+</sup>]<sub>i</sub> decay in hiPSCâCMs.</p></list-item><list-item><p>Relative contribution of SERCA, NCX, and slow mechanisms to [Ca<sup>2+</sup>]<sub>i</sub> extrusion in hiPSCâCMs.</p></list-item></list>Data information: <italic>nÂ </italic>=<italic>Â </italic>2â3 cells each from three independent experiments (meanÂ Â±Â SEM); *<italic>PÂ </italic>&lt;<italic>Â </italic>0.05, statistical significance was assessed with oneâway ANOVA on ranks followed by Dunn's test in case of failed normality or variance. Otherwise, oneâway ANOVA followed by StudentâNewmanâKeuls test was used.</p>
          </caption>
          <graphic id="nlm-graphic-13" xlink:href="EMMM-8-1390-g006"/>
        </fig>
        <p>The amplitude of caffeineâevoked [Ca<sup>2+</sup>]<sub>i</sub> transients in the presence of NiCl<sub>2</sub> was considerably lower in TECRL<sub>Hom</sub>âhiPSCâCMs compared with CTRLâhiPSCâCMs (FigÂ <xref rid="emmm201505719-fig-0005" ref-type="fig">5</xref>B). However, fractional Ca<sup>2+</sup> release, which is a measure of the amplitude of the normal systolic [Ca<sup>2+</sup>]<sub>i</sub> transient as a fraction of the amplitude of caffeineâevoked [Ca<sup>2+</sup>]<sub>i</sub> transient in the presence of NiCl<sub>2</sub>, did not differ significantly between the groups (FigÂ <xref rid="emmm201505719-fig-0005" ref-type="fig">5</xref>B). <italic>K</italic>
<sub>SERCA</sub> and <italic>K</italic>
<sub>NCX</sub> were significantly lower in TECRL<sub>Hom</sub>âhiPSCâCMs compared with CTRLâhiPSCâCMs (FigÂ <xref rid="emmm201505719-fig-0005" ref-type="fig">5</xref>C). <italic>K</italic>
<sub>slow mechanisms</sub> indicated by the rate of Ca<sup>2+</sup> transient decay in the presence of caffeine, and NiCl<sub>2</sub> (<italic>K</italic>
<sub>Caff+Ni</sub>) was not affected in TECRL<sub>Hom</sub>âhiPSCâCMs (FigÂ <xref rid="emmm201505719-fig-0005" ref-type="fig">5</xref>C).</p>
        <p>Although SERCA and NCX activities were lower in TECRL<sub>Hom</sub>âhiPSCâCMs, the relative contribution of SERCA, NCX, and slow mechanisms to [Ca<sup>2+</sup>]<sub>i</sub> transient decay did not differ significantly between the groups (FigÂ <xref rid="emmm201505719-fig-0005" ref-type="fig">5</xref>D). SERCA and NCX removed â65â70% and 25â30% of the activator Ca<sup>2+</sup> from the cytosol, respectively, whereas the mitochondrial Ca<sup>2+</sup> uptake and sarcolemmal Ca<sup>2+</sup>âATPase accounted for the removal of &lt;Â 8% of [Ca<sup>2+</sup>]<sub>i</sub>.</p>
        <p>The [Ca<sup>2+</sup>]<sub>i</sub> transient properties of TECRL<sub>Het</sub>âhiPSCâCMs were largely in between CTRLâhiPSCâCMs and TECRL<sub>Hom</sub>âhiPSCâCMs, suggesting a gene dosage dependency (FigsÂ <xref rid="emmm201505719-fig-0004" ref-type="fig">4</xref>B and C, and <xref rid="emmm201505719-fig-0005" ref-type="fig">5</xref>BâD).</p>
      </sec>
      <sec id="emmm201505719-sec-0011">
        <title>TECRL<sub>Hom</sub>âhiPSCâCMs and hESCâCMs with <italic>TECRL</italic> knockdown exhibit prolonged APs</title>
        <p>Increased diastolic [Ca<sup>2+</sup>]<sub>i</sub> is believed to be a substrate for delayed afterdepolarizations (DADs) leading to triggered arrhythmias which maybe further aggravated by catecholaminergic stimulation. TECRL<sub>Hom</sub>âhiPSCâCMs showed elevated diastolic [Ca<sup>2+</sup>]<sub>i</sub> which prompted us to investigate their action potential (AP) properties. We also studied the AP parameters of hESCâCMs with <italic>TECRL</italic> knockdown in order to compare their electrophysiological phenotype to TECRL<sub>Hom</sub>âhiPSCâCMs.</p>
        <p>First, we studied the AP properties of TECRL<sub>Hom</sub>âhiPSCâCMs (FigÂ <xref rid="emmm201505719-fig-0006" ref-type="fig">6</xref>A). Representative APs and averaged AP parameters of hiPSCâCMs from CTRL, TECRL<sub>Het</sub>, and TECRL<sub>Hom</sub> lines paced at 1âHz are shown in FigÂ <xref rid="emmm201505719-fig-0006" ref-type="fig">6</xref>B and C. Average resting membrane potential (RMP), maximum upstroke velocity (d<italic>V</italic>/d<italic>t</italic>
<sub>max</sub>), maximal AP amplitude (APA<sub>max</sub>), and AP plateau amplitude (APA<sub>plat</sub>) did not differ significantly between the three groups (FigÂ <xref rid="emmm201505719-fig-0006" ref-type="fig">6</xref>C). However, APs of TECRL<sub>Hom</sub>âhiPSCâCMs displayed marked prolongation of AP duration (APD) at 20% repolarization (APD<sub>20</sub>) and there was a clear trend for an increase in APD at 50% (APD<sub>50</sub>) and 90% (APD<sub>90</sub>) repolarization compared to CTRLâhiPSCâCMs (FigÂ <xref rid="emmm201505719-fig-0006" ref-type="fig">6</xref>C).</p>
        <fig fig-type="Figure" xml:lang="en" id="emmm201505719-fig-0006" orientation="portrait" position="float">
          <label>Figure 6</label>
          <caption>
            <title>
<styled-content style="fixed-case">AP</styled-content> characteristics of <styled-content style="fixed-case">TECRL</styled-content>âhi<styled-content style="fixed-case">PSC</styled-content>â<styled-content style="fixed-case">CM</styled-content>s</title>
            <p>
<list list-type="alpha-upper" id="emmm201505719-list-0007"><list-item><p>AP illustrating the analyzed parameters.</p></list-item><list-item><p>Representative APs from control (CTRL), heterozygous (HET), and homozygous (HOM) CMs.</p></list-item><list-item><p>RMP, d<italic>V</italic>/d<italic>t</italic>
<sub>max,</sub> APAmax, APAplat, APD<sub>20</sub>, APD<sub>50</sub>, and APD<sub>90</sub> of CTRLâ, TECRL<sub>Het</sub>â, and TECRL<sub>Hom</sub>âhiPSCâCMs.</p></list-item></list>Data information: <italic>nÂ </italic>=<italic>Â </italic>3â4 cells each from three independent experiments (meanÂ Â±Â SEM); *<italic>PÂ </italic>&lt;<italic>Â </italic>0.05, statistical significance was assessed with oneâway ANOVA on ranks followed by Dunn's test in case of failed normality or variance. Otherwise, oneâway ANOVA followed by StudentâNewmanâKeuls test was used. APÂ =Â action potential; APA<sub>max</sub>Â =Â maximum AP amplitude, APA<sub>plat</sub>Â =Â AP plateau amplitude; APD<sub>20</sub>, APD<sub>50</sub>, and APD<sub>90</sub>Â =Â AP duration at 20, 50, and 90% repolarization, respectively; d<italic>V</italic>/d<italic>t</italic>
<sub>max</sub>Â = maximum upstroke velocity; RMPÂ =Â resting membrane potential.</p>
          </caption>
          <graphic id="nlm-graphic-15" xlink:href="EMMM-8-1390-g007"/>
        </fig>
        <p>Next, we performed lentiviral short hairpin (sh) RNAâmediated knockdown of <italic>TECRL</italic> in hESCâCMs to study their AP properties. Lentiviral vectors encoding five different <italic>TECRL</italic>âspecific shRNAs (<xref rid="emmm201505719-sup-0001" ref-type="supplementary-material">AppendixÂ TableÂ S3</xref>) for <italic>TECRL</italic> were tested in hESCâCMs, two of which (<italic>TECRL</italic>âsh#3 and <italic>TECRL</italic>âsh#4) gave efficient knockdown as assessed by RTâqPCR. Primer sequences are provided in <xref rid="emmm201505719-sup-0001" ref-type="supplementary-material">Appendix Table S4</xref>. However, following puromycin selection, hESCâCMs treated with <italic>TECRL</italic>âsh#4 showed pronounced cytotoxicity (<xref rid="emmm201505719-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S4A</xref>). Therefore, <italic>TECRL</italic>âsh#3 (hereinafter referred to as sh<italic>TECRL</italic>) was selected for further experiments and transduction in hESCâCMs resulted in 70% reduction in <italic>TECRL</italic> mRNA level in comparison with cells exposed to a control vector (sh<italic>CONTR</italic>; <xref rid="emmm201505719-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S4B</xref>). hESCâCMs transduced with sh<italic>CONTR</italic> or sh<italic>TECRL</italic> maintained their cardiac phenotype and knockdown of <italic>TECRL</italic> in hESCâCMs did not affect <italic>TNNT2</italic> expression (<xref rid="emmm201505719-sup-0001" ref-type="supplementary-material">AppendixÂ FigÂ S4B</xref>). AP parameters of sh<italic>CONTRâ</italic> or sh<italic>TECRLâ</italic>transduced hESCâCMs stimulated at 1âHz were recorded, and representative traces as well as averaged data are shown in <xref rid="emmm201505719-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S4C</xref> and <xref rid="emmm201505719-sup-0001" ref-type="supplementary-material">D</xref>. RMP, d<italic>V</italic>/d<italic>t</italic>
<sub>max</sub>, APA<sub>max</sub>, and APA<sub>plat</sub> did not differ significantly between the two experimental groups (<xref rid="emmm201505719-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S4D</xref>). However, hESCâCMs treated with sh<italic>TECRL</italic> displayed significantly prolonged APs as evidenced by the increase in APD<sub>20</sub>, APD<sub>50</sub>, and APD<sub>90</sub> values (<xref rid="emmm201505719-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S4D</xref>). In addition, Western blotting for canonical calciumâhandling proteins revealed a 56% decrease in RYR2 protein and 18% decrease in CASQ2 in sh<italic>TECRLâ</italic>treated hESCâCMs while SERCA2a, PLB, NCX1, and Ca<sub>v</sub>1.2 protein levels were unaffected (<xref rid="emmm201505719-sup-0001" ref-type="supplementary-material">AppendixÂ Fig S4E</xref>).</p>
      </sec>
      <sec id="emmm201505719-sec-0012">
        <title>TECRL<sub>Hom</sub>âhiPSCâCMs have an increased susceptibility to triggered activity</title>
        <p>To evaluate the susceptibility of TECRL<sub>Hom</sub>âhiPSCâCMs to triggered activity, we applied a fast pacing episode (3Â Hz; 10Â s), followed by a 10âs pause in the absence or presence of 10Â nM noradrenaline (NA). Representative traces of CTRLâhiPSCâCMs and TECRL<sub>Hom</sub>âhiPSCâCMs, in the absence and presence of NA, are shown in FigÂ <xref rid="emmm201505719-fig-0007" ref-type="fig">7</xref>A and C, respectively. In the absence of NA, the last stimulated AP (arrow) is followed by APs which seem to be due to diastolic depolarization rather than DADs (FigÂ <xref rid="emmm201505719-fig-0007" ref-type="fig">7</xref>A) since the frequency of such âtriggeredâ APs did not differ significantly between the experimental groups (FigÂ <xref rid="emmm201505719-fig-0007" ref-type="fig">7</xref>B). Moreover, the prevalence of âtriggeredâ and spontaneous APs (i.e., APs elicited without a fast pacing protocol) was also found to be similar in the absence of NA (FigÂ <xref rid="emmm201505719-fig-0007" ref-type="fig">7</xref>B), which further suggests that the âtriggeredâ APs in FigÂ <xref rid="emmm201505719-fig-0007" ref-type="fig">7</xref>A are not due to DADs. However, in the presence of NA, âtriggeredâ APs were abundantly present in TECRL<sub>Hom</sub>âhiPSCâCMs compared with CTRLâhiPSCâCMs (FigÂ <xref rid="emmm201505719-fig-0007" ref-type="fig">7</xref>C). The incidence of âtriggeredâ APs was also significantly higher than that of spontaneous APs (FigÂ <xref rid="emmm201505719-fig-0007" ref-type="fig">7</xref>D), indicating that the higher frequency of âtriggeredâ APs in TECRL<sub>Hom</sub>âhiPSCâCMs is due to DADs rather than spontaneous activity. Similar to what was observed for [Ca<sup>2+</sup>]<sub>i</sub> transient properties, AP properties and susceptibility to triggered activity of TECRL<sub>Het</sub>âhiPSCâCMs were largely in between those of CTRLâhiPSCâCMs and TECRL<sub>Hom</sub>âhiPSCâCMs.</p>
        <fig fig-type="Figure" xml:lang="en" id="emmm201505719-fig-0007" orientation="portrait" position="float">
          <label>Figure 7</label>
          <caption>
            <title>
<styled-content style="fixed-case">TECRL<sub>H</sub></styled-content>
<sub>om</sub>âhi<styled-content style="fixed-case">PSC</styled-content>â<styled-content style="fixed-case">CM</styled-content>s demonstrate increased susceptibility to triggered activity in response to <styled-content style="fixed-case">NA</styled-content>
</title>
            <p>
<list list-type="simple" id="emmm201505719-list-0008"><list-item><label>A, B</label><p>Representative AP traces (A) and averaged activity (B) of triggered and spontaneous activity in hiPSCâCMs in the absence of NA.</p></list-item><list-item><label>C, D</label><p>Representative AP traces (C) and averaged activity (D) of triggered and spontaneous activity in hiPSCâCMs in the presence of NA.</p></list-item></list>Data information: <italic>nÂ </italic>=<italic>Â </italic>3â4 cells each from three independent experiments (meanÂ Â±Â SEM); *<italic>PÂ </italic>&lt;<italic>Â </italic>0.05, statistical significance within a group before and after application of NA was assessed with paired <italic>t</italic>âtest or Wilcoxon signed rank test in case of failed normality; arrows in (A) and (C) indicate last stimulated AP. NAÂ =Â noradrenaline.</p>
          </caption>
          <graphic id="nlm-graphic-17" xlink:href="EMMM-8-1390-g008"/>
        </fig>
      </sec>
      <sec id="emmm201505719-sec-0013">
        <title>Effect of flecainide on hiPSCâCMs</title>
        <p>Flecainide, a class Ic antiarrhythmic drug, has been shown to be effective in CPVT patients, (Watanabe <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0042" ref-type="ref">2009</xref>; van der Werf <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0043" ref-type="ref">2011</xref>) although its precise mechanism of action has been a point of debate. To investigate whether flecainide has an effect on triggered activity of TECRL<sub>Hom</sub>âhiPSCâCMs, we administered 5Â Î¼M of the drug and analyzed AP properties.</p>
        <p>FigureÂ <xref rid="emmm201505719-fig-0008" ref-type="fig">8</xref>A shows typical APs of a TECRL<sub>Hom</sub>âhiPSCâCM in the absence and presence of flecainide. The average effects of flecainide on AP parameters in all three hiPSCâCM groups are summarized in FigÂ <xref rid="emmm201505719-fig-0008" ref-type="fig">8</xref>B. Flecainide reduced the d<italic>V</italic>/d<italic>t</italic>
<sub>max</sub> and caused AP prolongation in all three groups without affecting the RMP (FigÂ <xref rid="emmm201505719-fig-0008" ref-type="fig">8</xref>B). These effects did not differ significantly between the groups. FigureÂ <xref rid="emmm201505719-fig-0008" ref-type="fig">8</xref>C shows typical examples of triggered (top) and spontaneous (bottom) APs of a TECRL<sub>Hom</sub>âhiPSCâCM in the absence and presence of flecainide. The averaged effects of the drug on triggered and spontaneous activity in the three experimental groups are summarized in FigÂ <xref rid="emmm201505719-fig-0008" ref-type="fig">8</xref>D. While flecainide reduced the frequency of both triggered and spontaneous activity (FigÂ <xref rid="emmm201505719-fig-0008" ref-type="fig">8</xref>D), these reductions were not significantly different between the three groups. However, the reduction in triggered activity was more pronounced than that of spontaneous activity in TECRL<sub>Het</sub>âhiPSCâCMs and TECRL<sub>Hom</sub>âhiPSCâCMs (FigÂ <xref rid="emmm201505719-fig-0008" ref-type="fig">8</xref>D). These results suggest that a treatment regimen with flecainide might be effective in preventing arrhythmias in patients carrying the <italic>TECRL</italic>c.331+1G&gt;A mutation.</p>
        <fig fig-type="Figure" xml:lang="en" id="emmm201505719-fig-0008" orientation="portrait" position="float">
          <label>Figure 8</label>
          <caption>
            <title>Flecainide alleviates triggered activity in <styled-content style="fixed-case">TECRL<sub>H</sub></styled-content>
<sub>om</sub>âhi<styled-content style="fixed-case">PSC</styled-content>â<styled-content style="fixed-case">CM</styled-content>s</title>
            <p>
<list list-type="simple" id="emmm201505719-list-0009"><list-item><label>A</label><p>Representative AP trace of a TECRL<sub>Hom</sub>âhiPSCâCM in the presence of NA alone or NA and flecainide.</p></list-item><list-item><label>B</label><p>Effect of flecainide on AP parameters of hiPSCâCMs.</p></list-item><list-item><label>C, D</label><p>Addition of 5<bold>Â </bold>Î¼M of flecainide decreased the susceptibility to triggered activity in hiPSCâCMs. Note that the effect of flecainide on triggered activity of TECRL<sub>Het</sub>â and TECRL<sub>Hom</sub>âhiPSCâCMs is more pronounced than its effect on their spontaneous activity.</p></list-item></list>Data information: <italic>nÂ </italic>=<italic>Â </italic>1â2 cells each from three independent experiments (meanÂ Â±Â SEM); *<italic>PÂ </italic>&lt;<italic>Â </italic>0.05, statistical significance within a group before and after application of flecainide was assessed with paired <italic>t</italic>âtest; arrow in (C) indicates last stimulated AP. NAÂ =Â noradrenaline, FlecÂ =Â flecainide.</p>
          </caption>
          <graphic id="nlm-graphic-19" xlink:href="EMMM-8-1390-g009"/>
        </fig>
      </sec>
    </sec>
    <sec id="emmm201505719-sec-0014">
      <title>Discussion</title>
      <p>The etiology of a number of IADs remains unknown, and similar diagnostic challenges are seen in other cardiac diseases. For example, LQTS is a condition with monogenic inheritance for which hundreds of rare mutations have been reported in 16 genes (LQTS1â16). LQTS patients are grouped into distinct syndromes based on their clinical characteristics as well as their genotypes. However, 30% of patients are without a genetically confirmed diagnosis and remain at risk of cardiac events and sudden death (Tester &amp; Ackerman, <xref rid="emmm201505719-bib-0039" ref-type="ref">2006</xref>). Similarly, in CPVT, 35â45% of the patients without a known genetic cause remain at risk for adverse arrhythmic events (Ackerman <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0001" ref-type="ref">2011</xref>). WES has emerged as a means to meet this challenge (Biesecker &amp; Green, <xref rid="emmm201505719-bib-0009" ref-type="ref">2014</xref>). In the current study, we used WES to identify <italic>TECRL</italic> as a novel lifeâthreatening inherited arrhythmia gene associated with a recessive form of inherited arrhythmia with a clinical phenotype that has overlapping features of LQTS and CPVT.</p>
      <p>Clinically, affected individuals from the Sudanese family and both French Canadian cases presented with stressâinduced ventricular arrhythmias including SCD or aborted SCD. At rest, the QTc was normal or mildly prolonged while pharmacological sympathetic stimulation resulted in paradoxical QT prolongation as demonstrated in the French Canadian cases. Notably, affected individuals in the Sudanese family presented arrhythmias in childhood while the onset of symptoms in both French Canadian patients was in early adulthood. The most likely explanation for this difference in the age of onset is the more drastic effect of the splice site mutation identified in the Sudanese family. In all cases, the disease is highly penetrant and lifeâthreatening, with all affected individuals having experienced cardiac arrest at a young age. The French Canadian cases also showed recurrent stressâinduced AT, which sometimes triggered VT. In contrast, no atrial arrhythmia was documented in the Sudanese family. This may be due to the shorter followâup related to the high lethality of the disease, as well as differences in monitoring (the French Canadian patients have a dualâchamber ICDs, with continuous monitoring of the atrial ECG). The heart was structurally normal in all affected individuals, with the exception of two individuals in the Sudanese family that also had tetralogy of Fallot. Whether these congenital heart defects are part of the same syndrome or are caused by another genetic defect in this consanguineous family remains unclear. During longer followâup of the French Canadian cases, it was noted that less potent betaâblockers (metoprolol and bisoprolol) are associated with arrhythmia recurrence, while maximal tolerated doses of nadolol were highly effective.</p>
      <p>Whether the clinical phenotype should be classified as LQTS or CPVT is a subject of discussion. Despite having nearly identical phenotypes, the Sudanese family was diagnosed with CPVT, while the French Canadian cases were diagnosed with LQTS. The arrhythmias were induced by catecholaminergic stimulation, and most affected individuals had a normal baseline QTc, which together suggest CPVT. In contrast, mild QTc prolongation in some patients and the paradoxical QT prolongation during catecholaminergic stimulation indicate a LQTS phenotype (Obeyesekere <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0030" ref-type="ref">2011</xref>). Such an overlapping clinical phenotype is also observed in calmodulinârelated inherited arrhythmia (Makita <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0025" ref-type="ref">2014</xref>), as well as in <italic>KCNJ2</italic> mutations causing AndersenâTawil syndrome, which can present as LQTS or CPVT phenocopies (Kimura <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0020" ref-type="ref">2012</xref>). Therefore, we recommend that a homozygous mutation in <italic>TECRL</italic> should be considered as a possible cause of the etiology in patients presenting with stressâinduced complex ventricular arrhythmias or cardiac arrest at a young age, whether they are diagnosed with (geneâelusive) LQTS or CPVT. The identification of additional families with the same syndrome and genetic defect could help in better characterizing/categorizing the phenotype.</p>
      <p>Using murine and human tissues as well as cell lines, we showed that <italic>TECRL</italic> expression is restricted to cardiac and skeletal muscles and that most of the TECRL protein is localized to the ER, which is a critical site of protein, lipid, and glucose metabolism as well as calcium homeostasis. Accordingly, reactome pathway analysis indicates a role for <italic>TECRL</italic> in fatty acid and lipid metabolism while gene ontology annotates its function as an enzyme involved in catalysis of redox reactions. In the adult heart, free fatty acids are the primary substrate for energy production at rest and abnormalities in fatty acid oxidation have been linked to arrhythmias (Bonnet <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0012" ref-type="ref">1999</xref>). Perturbations in physiological levels of lipids/fatty acids and metabolic function can have direct consequences on ion channels and calciumâhandling proteins (Charnock, <xref rid="emmm201505719-bib-0015" ref-type="ref">1994</xref>; Boland &amp; Drzewiecki, <xref rid="emmm201505719-bib-0011" ref-type="ref">2008</xref>; Barth &amp; Tomaselli, <xref rid="emmm201505719-bib-0003" ref-type="ref">2009</xref>). Further studies are necessary to elucidate the role of <italic>TECRL</italic> in lipid metabolism and how mutations are linked to cardiac arrhythmias.</p>
      <p>hiPSCs offer important opportunities to model cardiac diseases <italic>inÂ vitro</italic> and are especially valuable when myocardial tissue of the patient is not accessible to determine the consequences of a particular mutation. Using hiPSCâCMs, we demonstrated that the <italic>TECRL</italic> mRNA in TECRL<sub>Hom</sub>âhiPSCâCMs lacks exon 3 and that these cells recapitulate salient features of the disease phenotype.</p>
      <p>Altered calcium homeostasis is a hallmark of CPVT phenotype, and mutations in <italic>RYR2</italic> or <italic>CASQ2</italic> have been identified to cause this disease. Interestingly, protein levels of RYR2 and CASQ2 were significantly downregulated in TECRL<sub>Hom</sub>âhiPSCâCMs. We also found a smaller [Ca<sup>2+</sup>]<sub>i</sub> transient amplitude in these CMs. Since the Ca<sup>2+</sup> concentration in the SR is a major regulator of the [Ca<sup>2+</sup>]<sub>i</sub> transient amplitude, this finding suggests a lower SR Ca<sup>2+</sup> content in TECRL<sub>Hom</sub>âhiPSCâCMs. Indeed, caffeineâevoked transients in the presence of 10Â mM NiCl<sub>2</sub>, which are an indicator of SR Ca<sup>2+</sup> content, were significantly lower in TECRL<sub>Hom</sub>âhiPSCâCMs, which could be associated with downregulation of RYR2.</p>
      <p>Additionally, the diastolic [Ca<sup>2+</sup>]<sub>i</sub> concentration was significantly higher in TECRL<sub>Hom</sub>âhiPSCâCMs than in CTRLâhiPSCâCMs, which could explain their increased propensity to DADs upon adrenergic stimulation with NA. The increase in diastolic [Ca<sup>2+</sup>]<sub>i</sub> in TECRL<sub>Hom</sub>âhiPSCâCMs may in part be reasoned by the observed decrease in SERCA and NCX activity. Although we did not observe a decrease in protein levels of SERCA2A and NCX in TECRL<sub>Hom</sub>âhiPSCâCMs compared with CTRLâhiPSCâCMs, we noted a decrease in their activity by functional studies. It has been established that a number of postâtranslational modifications regulate the activity of ionophoric proteins, which could clarify the observed effects (Ruknudin <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0035" ref-type="ref">2007</xref>; Stammers <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0037" ref-type="ref">2015</xref>). Decreased NCX activity has been shown to reduce DAD amplitude resulting in fewer spontaneous APs (BÃ¶geholz <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0010" ref-type="ref">2015</xref>). However, in our model, despite a lower NCX activity in TECRL<sub>Hom</sub>âhiPSCâCMs compared with CTRLâhiPSCâCMs, the increased diastolic [Ca<sup>2+</sup>]<sub>i</sub> was sufficient to induce DADs and subsequent triggered APs.</p>
      <p>We also assessed the relative contribution of SERCA, NCX, and the slow mechanisms to [Ca<sup>2+</sup>]<sub>i</sub> removal from the cytosol. In isolated adult ventricular CMs, the decline of the [Ca<sup>2+</sup>]<sub>i</sub> transient is mainly due to reuptake of Ca<sup>2+</sup> into the SR by SERCA and extrusion of Ca<sup>2+</sup> via sarcolemmal NCX with a minor contribution of the slow mechanisms (Bers, <xref rid="emmm201505719-bib-0007" ref-type="ref">2006</xref>; Dibb <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0019" ref-type="ref">2007</xref>). Our results correlate with this existing data suggesting that the Ca<sup>2+</sup> transport systems in hiPSCâCMs are similar to those reported in adult human and animal CMs (Bers, <xref rid="emmm201505719-bib-0006" ref-type="ref">2000</xref>).</p>
      <p>At the single cell level, APs of TECRL<sub>Hom</sub>âhiPSCâCMs showed an increase in APD<sub>20</sub>. Although not significant, APD<sub>50</sub> and APD<sub>90</sub> were also prolonged, compatible with the borderline QTc prolongation in some of the Sudanese patients or with repolarization abnormalities with QT prolongation occasionally seen on the resting ECG of patient 1. Interestingly, hESCâCMs with <italic>TECRL</italic> knockdown exhibited markedly prolonged APD<sub>20</sub>, APD<sub>50</sub>, and APD<sub>90</sub>. Collectively, these findings are consistent with an overlapping LQTS/CPVT phenotype in TECRL<sub>Hom</sub>âhiPSCâCMs manifested by APD prolongation (LQTS) as well as a disturbed calcium handling and increased propensity for DADs during catecholaminergic stimulation (CPVT).</p>
      <p>Finally, we demonstrated that the antiarrhythmic drug flecainide suppressed the incidence of triggered APs in TECRL<sub>Hom</sub>âhiPSCâCMs. Flecainide was first classified as a blocker of Na<sup>+</sup> current (I<sub>Na</sub>), and more recently, it has been shown to reduce exerciseâinduced arrhythmias in CPVT patients (Watanabe <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0042" ref-type="ref">2009</xref>; van der Werf <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0043" ref-type="ref">2011</xref>). In agreement with flecainide's effect as I<sub>Na</sub> blocker, we observed a decrease in AP upstroke velocity. We also observed AP prolongation, as previously reported in isolated human cardiac tissue (Wang <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0041" ref-type="ref">1990</xref>). The precise mechanisms by which flecainide exerts an antiarrhythmic effect is unclear, but has been proposed to be due to reduced opening of RYR2 channels (Watanabe <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0042" ref-type="ref">2009</xref>) or I<sub>Na</sub> blockade resulting in decreased excitability (Liu <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0024" ref-type="ref">2011</xref>; Bannister <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0002" ref-type="ref">2015</xref>), or a combination of both (Watanabe <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0042" ref-type="ref">2009</xref>). Although not conclusive, our results suggest that depression of the upstroke velocity of the AP and the consequential decrease in excitability contributes to the observed reduction in triggered activity. It is encouraging that flecainide reduced the incidence of triggered activity in TECRL<sub>Hom</sub>âhiPSCâCMs. However, some DADs were still observed emphasizing the need for additional or more effective drugs to prevent their occurrence in TECRL<sub>Hom</sub>âhiPSCâCMs. Moreover, the I<sub>Kr</sub> blocking and consequential QTâprolonging effect of flecainide may potentially offset its beneficial effect on the triggered activity. CMs generated from patientâspecific hiPSCs were valuable to study the functional consequences of the c.331+1G&gt;A mutation in <italic>TECRL</italic>. The apparent immature phenotype of hiPSCâCMs (e.g., APDÂ &lt;Â 200Â ms) as opposed to freshly isolated human adult ventricular CMs evidently did not preclude their use in disease modeling.</p>
      <p>In conclusion, we identified a novel highly lethal autosomal recessive inherited arrhythmia syndrome caused by homozygous mutations in <italic>TECRL</italic> in patients from three different families. Both clinical data from patients and cellular functional data from hiPSCâCMs point toward overlapping features of LQTS and CPVT with triggered activityâmediated arrhythmogenesis. Further studies are needed to elucidate the exact mechanisms underlying the electrical phenotype and to assess the prevalence of <italic>TECRL</italic> mutations in LQTS, CPVT, and cases of unexplained cardiac arrest. hiPSC lines from more patients or introduction of targeted mutations in healthy control lines may be of value in this context. Screening for mutations in <italic>TECRL</italic> should be considered in selected cases of suspected autosomal recessive inherited arrhythmia syndromes.</p>
    </sec>
    <sec id="emmm201505719-sec-0015">
      <title>Materials and Methods</title>
      <sec id="emmm201505719-sec-0016">
        <title>Ethics statement</title>
        <p>The French Canadian subjects described in this study were recruited at the Cardiovascular Genetics Center of the Montreal Heart Institute. Informed consent was obtained for both subjects according to procedures approved by the Montreal Heart Institute Ethics Review Board. Signed informed consent was also obtained from participating patients from the Sudanese family or their guardians, the study adhered to the Declaration of Helsinki, and the research protocol was approved by the Al Ain Medical District Human Research Ethics Committee, College of Medicine, United Arab Emirates (UAE) University. Study on hESCs and hiPSCs was performed in the Netherlands, and their use was approved by the Medical Ethics Committee of Leiden University Medical Center (LUMC).</p>
      </sec>
      <sec id="emmm201505719-sec-0017">
        <title>Clinical data analysis</title>
        <sec id="emmm201505719-sec-0018">
          <title>French Canadian subjects</title>
          <p>Clinical data, including the resting ECGs and 24âh Holter recordings, were collected and evaluated. Clinical data of family members were evaluated when possible.</p>
        </sec>
        <sec id="emmm201505719-sec-0019">
          <title>Sudanese family</title>
          <p>Clinical data of family members (where possible), including baseline ECGs, exercise ECGs, and 24âh Holter recordings, were collected and evaluated. Family members who experienced sudden cardiac death at young age or who demonstrated arrhythmias were considered affected.</p>
        </sec>
      </sec>
      <sec id="emmm201505719-sec-0020">
        <title>Exome sequencing</title>
        <p>Detailed methods are provided in the <xref rid="emmm201505719-sup-0001" ref-type="supplementary-material">Appendix</xref>.</p>
        <sec id="emmm201505719-sec-0021">
          <title>French Canadian subjects</title>
          <p>Genomic DNA from both patients was extracted from peripheral blood. A single family member, the father of patient 2, was available for followâup genetic testing and was found to be heterozygous for the Arg196Gln mutation in <italic>TECRL</italic>.</p>
        </sec>
        <sec id="emmm201505719-sec-0022">
          <title>Sudanese family</title>
          <p>Genomic DNA from individuals III:1, III:2, IV:2, and IV:10 (FigÂ <xref rid="emmm201505719-fig-0001" ref-type="fig">1</xref>D) was extracted from peripheral blood lymphocytes, and WES was carried out at the Beijing Genomics Institute (BGI; Shenzhen, China).</p>
        </sec>
      </sec>
      <sec id="emmm201505719-sec-0023">
        <title>Reprogramming of primary fibroblasts to induced pluripotent stem cells</title>
        <p>Primary fibroblasts from members of the affected family were isolated from skin biopsies with informed consent under protocols approved by the Al Ain Hospital Ethics Committee for Research, SEHA, Abu Dhabi, UAE. Lowâpassage skin fibroblasts were reprogrammed to induced pluripotent stem cells using nonâintegrating Sendai virus vectors encoding OCT4, SOX2, KLF4, and MYC as described previously (Zhang <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0045" ref-type="ref">2014</xref>). Official identification of the cell lines used in this study is as follows: LUMC0046iTECRL (hiPSCs with heterozygous <italic>TECRL</italic>c.331+1G&gt;A mutation); LUMC0047iCTRL (control hiPSCs); and LUMC0048iTECRL (hiPSCs with homozygous <italic>TECRL</italic>c.331+1G&gt;A mutation).</p>
        <p>Of several hiPSC clones with embryonic stem cell morphology those showing robust expression of pluripotency markers, OCTâ4, NANOG, SSEA4, and/or TRAâ181, as analyzed by flow cytometry or by immunocytochemistry, were selected for further study. These hiPSC lines were karyotyped and subjected to a global assessment of pluripotency by PluriTest (MÃ¼ller <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0027" ref-type="ref">2011</xref>).</p>
      </sec>
      <sec id="emmm201505719-sec-0024">
        <title>Maintenance of hiPSC lines and differentiation to CMs</title>
        <p>hiPSC lines were maintained in a feederâfree culture in mTESR1 medium (STEMCELL Technologies) on Matrigel (BD Biosciences) and passaged once a week with 1Â mg/ml dispase (Gibco).</p>
        <p>To induce cardiac differentiation, cells were seeded in a high density on Matrigel and supplemented with mTESR1 medium. Two days postâseeding, mTESR1 medium was replaced with BPEL medium (Ng <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0028" ref-type="ref">2008</xref>) containing 20Â ng/ml activinâA (R&amp;D systems), 20Â ng/ml BMP4 (R&amp;D systems), and 1.5Â Î¼mol/l CHIR99021 (Axon Medchem). On day 3, the medium was replaced with BPEL medium containing 5Â Î¼mol/l XAV939 (Tocris Biosciences). Cells received BPEL medium on day 7 and every 3â4Â days thereafter. Beating CMs were first seen in culture at day 10.</p>
      </sec>
      <sec id="emmm201505719-sec-0025">
        <title>AP measurements</title>
        <p>hiPSCâCMs were dissociated to single cells at day 20 using TrypLE<sup>â¢</sup> Select (Life Technologies) and plated on Matrigelâcoated coverslips. APs were recorded 10Â days after dissociation with the amphotericinâperforated patchâclamp technique as described previously (Devalla <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0017" ref-type="ref">2015</xref>) and further detailed in the <xref rid="emmm201505719-sup-0001" ref-type="supplementary-material">Appendix</xref>.</p>
      </sec>
      <sec id="emmm201505719-sec-0026">
        <title>Ca<sup>2+</sup> measurements</title>
        <p>hiPSCâCMs were dissociated at day 20, and [Ca<sup>2+</sup>]<sub><italic>i</italic></sub> transients were measured 10Â days after dissociation in Indoâ1 AM (Molecular Probes, Eugene, OR, USA) loaded cells as described before (van Borren <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0013" ref-type="ref">2010</xref>; Verkerk <italic>etÂ al</italic>, <xref rid="emmm201505719-bib-0040" ref-type="ref">2015</xref>) and elaborated in the <xref rid="emmm201505719-sup-0001" ref-type="supplementary-material">Appendix</xref>.</p>
      </sec>
      <sec id="emmm201505719-sec-0027">
        <title>Statistics</title>
        <p>Experiments with hiPSCâCMs were performed on cells obtained from <italic>nÂ </italic>â¥<italic>Â </italic>3 independent differentiations. Statistical analysis was carried out with SigmaStat 3.5 software, and data are presented as meanÂ Â±Â standard error of the mean. Normality and equal variance assumptions were tested with the KolmogorovâSmirnov and the Levene median test, respectively. Groups were compared using oneâway analysis of variance (ANOVA) followed by pairwise comparison using the StudentâNewmanâKeuls test or, in cases of failed normality and/or equal variance test, ANOVA based on ranks (KruskalâWallis test) followed by Dunn's test. <italic>PÂ </italic>&lt;<italic>Â </italic>0.05 was considered statistically significant.</p>
      </sec>
    </sec>
    <sec id="emmm201505719-sec-0029">
      <title>Author contributions</title>
      <p>LAâG and EHA enrolled the Sudanese patient family into the study with necessary approvals and collected clinical data and blood samples/biopsies; MT, LR, and MâAC enrolled the French Canadian patient families into the study with necessary approvals and collected clinical data and blood samples; JS, MT, MâAC, RT, and AAMW analyzed the clinical data; ZAB initiated wholeâexome sequencing of the Sudanese family members, carried out validation of identified variants by Sanger sequencing and coordinated the study; HJ performed exome sequencing; HJ, ZK, BS, and ALB analyzed exome sequencing data; JDR and MT initiated wholeâexome sequencing of French Canadian samples; AA performed exome sequencing; MâAC, FL, and PG analyzed exome sequencing data; PG and AA carried out validation of identified variants by Sequenom Mass Array genotyping; AA and RG performed experiments; PG and RG performed data analysis and interpretation; HDD and RP designed the hiPSC research. HDD and CF generated the hiPSC lines; HDD, AB, TZ, GK, JJMâK, MH, and AOV performed experiments with the hiPSC lines; HDD, AB, GK, JJMâK, AOV, and RP performed analysis and interpretation of data from hiPSC lines; AB performed <italic>TECRL</italic> expression studies in mouse and subâcellular localization experiments in cell lines; AAFV produced the lentiviral vectors for the <italic>TECRL</italic> knockdown studies; HDD, AOV, RP, RT, RG, and JDR wrote the manuscript with contributions from all the authors. CLM provided input on the design of the study and edited the manuscript. All authors read, provided input, and approved the manuscript.</p>
    </sec>
    <sec id="emmm201505719-sec-0030">
      <title>Conflict of interest</title>
      <p>The authors declare that they have no conflict of interest.</p>
    </sec>
    <sec id="emmm201505719-sec-0031">
      <boxed-text position="float" content-type="box" id="emmm201505719-blk-0001" orientation="portrait">
        <caption>
          <title>The paper explained</title>
        </caption>
        <sec id="emmm201505719-sec-0032">
          <title>Problem</title>
          <p>Inherited arrhythmogenic disorders are one of the leading causes of sudden cardiac death (SCD). However, 30% of SCD cases are due to unknown gene mutations.</p>
        </sec>
        <sec id="emmm201505719-sec-0033">
          <title>Results</title>
          <p>Here, we presented the clinical phenotype of patients from three different families with exerciseâinduced arrhythmias and identified mutations in the gene, <italic>TECRL</italic> by wholeâexome sequencing. We generated human induced pluripotent stem cells (hiPSCs) from an affected patient and differentiated these to cardiomyocytes (CMs). We uncovered electrophysiological and calciumâhandling abnormalities in CMs with a <italic>TECRL</italic> mutation compared to hiPSCâCMs generated from an unaffected family member. Moreover, mutant cells were prone to an increase in triggered electrical activity upon catecholaminergic stimulation with noradrenaline. This could be partially rescued by treatment with a class Ic antiarrhythmic drug, flecainide.</p>
        </sec>
        <sec id="emmm201505719-sec-0034">
          <title>Impact</title>
          <p>Our study demonstrated that <italic>TECRL</italic> mutations are associated with a complex clinical phenotype with characteristics of both long QT syndrome (LQTS) and catecholaminergic polymorphic ventricular tachycardia (CPVT). Screening for mutations in <italic>TECRL</italic> should be implemented in symptomatic patient cohorts negative for mutations in classical LQTS and CPVT genes. This study also reiterates the importance of hiPSC models, especially valuable to assess the effect of novel gene variants on disease phenotype. In summary, findings presented in this study have major implications for improving diagnosis and management of inherited arrhythmia syndromes.</p>
        </sec>
      </boxed-text>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supporting information</title>
      <supplementary-material content-type="local-data"/>
      <supplementary-material content-type="local-data" id="emmm201505719-sup-0001">
        <caption>
          <p>Appendix</p>
        </caption>
        <media xlink:href="EMMM-8-1390-s001.pdf">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="emmm201505719-sup-0002">
        <caption>
          <p>Source Data for Appendix</p>
        </caption>
        <media xlink:href="EMMM-8-1390-s002.zip">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data">
        <caption>
          <p>Review Process File</p>
        </caption>
        <media xlink:href="EMMM-8-1390-s004.pdf">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="emmm201505719-supp-data-0001">
        <caption>
          <p>Source Data for Figure 3</p>
        </caption>
        <media xlink:href="EMMM-8-1390-s003.pdf">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack id="emmm201505719-sec-0028">
      <title>Acknowledgements</title>
      <p>Funding for this study from the following sources is gratefully acknowledged: the Netherlands Organization for Health Research and Development (ZonMwâTOP 40â00812â98â12086) to H.D.D and (ZonMwâMKMDâ40â42600â98â036) to R.P; European Research Council advanced grant (STEMCARDIOVASCâ323182) to C.L.M; the Leenaards Foundation, the Swiss Institute of Bioinformatics, and the Swiss National Science Foundation (31003Aâ143914, 51RTP0_151019) grants to Z.K; Fondation Suisse de Cardiologie (No. 29283) to Z.A.B; the Netherlands CardioVascular Research Initiative, the Dutch Heart Foundation, Dutch Federation of University Medical Centers, the Netherlands Organization for Health Research and Development, and the Royal Netherlands Academy of Sciences (CVONâPREDICT) to A.A.M.W; Fondation de l'Institut de cardiologie de MontrÃ©al to JDR; and the Phillipa and Marvin Carsley Chair of Medicine of the University of Montreal to MT and RT. The authors thank the following people for contributing to the research presented in this manuscript: Laura Robb and Dr Blandine MondÃ©sert of the Cardiovascular Genetics Center of the Montreal Heart Institute for their assistance in the characterization of the French Canadian probands and family members; Prof. Jacques S. Beckmann for initiating the nextâgeneration sequence study of the Sudanese family and incorporating this family for exome sequencing; Dr Tom van Wezel (Department of Pathology, LUMC) for helpful discussions; M. Ohtaka, K. Nishimura, and M. Nakanishi (National Institute of Advanced Industrial Science and Technology, Japan) for providing the Sendai virus vectors; S. van de Pas and A. ât Jong from the LUMC hiPSC core facility for support with reprogramming; D. de Jong, K. Szuhai, and H. Tanke (Department of Molecular Cell Biology, LUMC) for karyotyping, Verena Schwach (Department of Anatomy &amp; Embryology, LUMC) for support with cell culture, and Annemarie Kip (Department of Cardiology, LUMC) for help with the lentiviral vector production. The computations were performed at the VitalâIT Center (<ext-link ext-link-type="uri" xlink:href="http://www.vital-it.ch">http://www.vital-it.ch</ext-link>) for highâperformance computing of the SIB Swiss Institute of Bioinformatics. The authors are especially grateful to the patient families for tissue samples and their consent for the study.</p>
    </ack>
    <ref-list content-type="cited-references" id="emmm201505719-bibl-0001">
      <title>References</title>
      <ref id="emmm201505719-bib-0001">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0001">
<string-name>
<surname>Ackerman</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Priori</surname>
<given-names>SG</given-names>
</string-name>, <string-name>
<surname>Willems</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Berul</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Brugada</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Calkins</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Camm</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Ellinor</surname>
<given-names>PT</given-names>
</string-name>, <string-name>
<surname>Gollob</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hamilton</surname>
<given-names>R</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2011</year>) <article-title>HRS/EHRA expert consensus statement on the state of genetic testing of the channelopathies and cardiomyopathies</article-title>. <source>Europace</source>
<volume>13</volume>: <fpage>1077</fpage>â<lpage>1109</lpage>
<pub-id pub-id-type="pmid">21810866</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0002">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0002">
<string-name>
<surname>Bannister</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Thomas</surname>
<given-names>NL</given-names>
</string-name>, <string-name>
<surname>Sikkel</surname>
<given-names>MB</given-names>
</string-name>, <string-name>
<surname>Mukherjee</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Maxwell</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>MacLeod</surname>
<given-names>KT</given-names>
</string-name>, <string-name>
<surname>George</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Williams</surname>
<given-names>AJ</given-names>
</string-name> (<year>2015</year>) <article-title>The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2</article-title>. <source>Circ Res</source>
<volume>116</volume>: <fpage>1324</fpage>â<lpage>1335</lpage>
<pub-id pub-id-type="pmid">25648700</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0003">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0003">
<string-name>
<surname>Barth</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Tomaselli</surname>
<given-names>GF</given-names>
</string-name> (<year>2009</year>) <article-title>Cardiac metabolism and arrhythmias</article-title>. <source>Circ Arrhythm Electrophysiol</source>
<volume>2</volume>: <fpage>327</fpage>â<lpage>335</lpage>
<pub-id pub-id-type="pmid">19808483</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0004">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0004">
<string-name>
<surname>Bassani</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Bers</surname>
<given-names>DM</given-names>
</string-name> (<year>1995</year>) <article-title>Rate of diastolic Ca release from the sarcoplasmic reticulum of intact rabbit and rat ventricular myocytes</article-title>. <source>Biophys J</source>
<volume>68</volume>: <fpage>2015</fpage>â<lpage>2022</lpage>
<pub-id pub-id-type="pmid">7612843</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0005">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0005">
<string-name>
<surname>Beqqali</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kloots</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wardâvan Oostwaard</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Mummery</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Passier</surname>
<given-names>R</given-names>
</string-name> (<year>2006</year>) <article-title>Genomeâwide transcriptional profiling of human embryonic stem cells differentiating to cardiomyocytes</article-title>. <source>Stem Cells</source>
<volume>24</volume>: <fpage>1956</fpage>â<lpage>1967</lpage>
<pub-id pub-id-type="pmid">16675594</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0006">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0006">
<string-name>
<surname>Bers</surname>
<given-names>DM</given-names>
</string-name> (<year>2000</year>) <article-title>Calcium fluxes involved in control of cardiac myocyte contraction</article-title>. <source>Circ Res</source>
<volume>87</volume>: <fpage>275</fpage>â<lpage>281</lpage>
<pub-id pub-id-type="pmid">10948060</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0007">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0007">
<string-name>
<surname>Bers</surname>
<given-names>DM</given-names>
</string-name> (<year>2006</year>) <article-title>Altered cardiac myocyte Ca regulation in heart failure</article-title>. <source>Physiology</source>
<volume>21</volume>: <fpage>380</fpage>â<lpage>387</lpage>
<pub-id pub-id-type="pmid">17119150</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0008">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0008">
<string-name>
<surname>Bhuiyan</surname>
<given-names>ZA</given-names>
</string-name>, <string-name>
<surname>Hamdan</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Shamsi</surname>
<given-names>ET</given-names>
</string-name>, <string-name>
<surname>Postma</surname>
<given-names>AV</given-names>
</string-name>, <string-name>
<surname>Mannens</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Wilde</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>AlâGazali</surname>
<given-names>L</given-names>
</string-name> (<year>2007</year>) <article-title>A novel early onset lethal form of catecholaminergic polymorphic ventricular tachycardia maps to chromosome 7p14âp22</article-title>. <source>J Cardiovasc Electrophysiol</source>
<volume>18</volume>: <fpage>1060</fpage>â<lpage>1066</lpage>
<pub-id pub-id-type="pmid">17666061</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0009">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0009">
<string-name>
<surname>Biesecker</surname>
<given-names>LG</given-names>
</string-name>, <string-name>
<surname>Green</surname>
<given-names>RC</given-names>
</string-name> (<year>2014</year>) <article-title>Diagnostic clinical genome and Exome sequencing</article-title>. <source>N Engl J Med</source>
<volume>371</volume>: <fpage>1170</fpage>
</mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0010">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0010">
<string-name>
<surname>BÃ¶geholz</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Pauls</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Bauer</surname>
<given-names>BK</given-names>
</string-name>, <string-name>
<surname>Schulte</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Dechering</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Frommeyer</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Kirchhefer</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Goldhaber</surname>
<given-names>JI</given-names>
</string-name>, <string-name>
<surname>MÃ¼ller</surname>
<given-names>FU</given-names>
</string-name>, <string-name>
<surname>Eckardt</surname>
<given-names>L</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2015</year>) <article-title>Suppression of early and late afterdepolarizations by heterozygous knockout of the Na<sup>+</sup>/Ca<sup>2+</sup> exchanger in a murine model</article-title>. <source>Circ Arrhythm Electrophysiol</source>
<volume>8</volume>: <fpage>1210</fpage>â<lpage>1218</lpage>
<pub-id pub-id-type="pmid">26338832</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0011">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0011">
<string-name>
<surname>Boland</surname>
<given-names>LM</given-names>
</string-name>, <string-name>
<surname>Drzewiecki</surname>
<given-names>MM</given-names>
</string-name> (<year>2008</year>) <article-title>Polyunsaturated fatty acid modulation of voltageâgated ion channels</article-title>. <source>Cell Biochem Biophys</source>
<volume>52</volume>: <fpage>59</fpage>â<lpage>84</lpage>
<pub-id pub-id-type="pmid">18830821</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0012">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0012">
<string-name>
<surname>Bonnet</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Martin</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>de Lonlay</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Villain</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Jouvet</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Rabier</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Brivet</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Saudubray</surname>
<given-names>JM</given-names>
</string-name> (<year>1999</year>) <article-title>Arrhythmias and conduction defects as presenting symptoms of fatty acid oxidation disorders in children</article-title>. <source>Circulation</source>
<volume>100</volume>: <fpage>2248</fpage>â<lpage>2253</lpage>
<pub-id pub-id-type="pmid">10577999</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0013">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0013">
<string-name>
<surname>van Borren</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Verkerk</surname>
<given-names>AO</given-names>
</string-name>, <string-name>
<surname>Wilders</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Hajji</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Zegers</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Bourier</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Tan</surname>
<given-names>HL</given-names>
</string-name>, <string-name>
<surname>Verheijck</surname>
<given-names>EE</given-names>
</string-name>, <string-name>
<surname>Peters</surname>
<given-names>SLM</given-names>
</string-name>, <string-name>
<surname>Alewijnse</surname>
<given-names>AE</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2010</year>) <article-title>Effects of muscarinic receptor stimulation on Ca<sup>2+</sup> transient, cAMP production and pacemaker frequency of rabbit sinoatrial node cells</article-title>. <source>Basic Res Cardiol</source>
<volume>105</volume>: <fpage>73</fpage>â<lpage>87</lpage>
<pub-id pub-id-type="pmid">19639379</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0014">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0014">
<string-name>
<surname>Chaix</surname>
<given-names>MâA</given-names>
</string-name>, <string-name>
<surname>Koopman</surname>
<given-names>TT</given-names>
</string-name>, <string-name>
<surname>Goyette</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Alikashani</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Latour</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Fatah</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hamilton</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Rioux</surname>
<given-names>JD</given-names>
</string-name> (<year>2016</year>) <article-title>Novel <italic>CALM3</italic> mutations in pediatric long QT syndrome patients support a <italic>CALM3</italic>âspecific calmodulinopathy</article-title>. <source>Heart Rhythm</source>
<volume>2</volume>: <fpage>250</fpage>â<lpage>254</lpage>
</mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0015">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0015">
<string-name>
<surname>Charnock</surname>
<given-names>JS</given-names>
</string-name> (<year>1994</year>) <article-title>Lipids and cardiac arrhythmia</article-title>. <source>Prog Lipid Res</source>
<volume>33</volume>: <fpage>355</fpage>â<lpage>385</lpage>
<pub-id pub-id-type="pmid">7870738</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0016">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0016">
<string-name>
<surname>Crotti</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>CN</given-names>
</string-name>, <string-name>
<surname>Graf</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>De Ferrari</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Cuneo</surname>
<given-names>BF</given-names>
</string-name>, <string-name>
<surname>Ovadia</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Papagiannis</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Feldkamp</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Rathi</surname>
<given-names>SG</given-names>
</string-name>, <string-name>
<surname>Kunic</surname>
<given-names>JD</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2013</year>) <article-title>Calmodulin mutations associated with recurrent cardiac arrest in infants</article-title>. <source>Circulation</source>
<volume>127</volume>: <fpage>1009</fpage>â<lpage>1017</lpage>
<pub-id pub-id-type="pmid">23388215</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0017">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0017">
<string-name>
<surname>Devalla</surname>
<given-names>HD</given-names>
</string-name>, <string-name>
<surname>Schwach</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Ford</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Milnes</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>ElâHaou</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Jackson</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Gkatzis</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Elliott</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Chuva de Sousa Lopes</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Mummery</surname>
<given-names>CL</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2015</year>) <article-title>Atrialâlike cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrialâselective pharmacology</article-title>. <source>EMBO Mol Med</source>
<volume>7</volume>: <fpage>394</fpage>â<lpage>410</lpage>
<pub-id pub-id-type="pmid">25700171</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0018">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0018">
<string-name>
<surname>DÃ­az</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Graham</surname>
<given-names>HK</given-names>
</string-name>, <string-name>
<surname>Trafford</surname>
<given-names>AW</given-names>
</string-name> (<year>2004</year>) <article-title>Enhanced sarcolemmal Ca<sup>2+</sup> efflux reduces sarcoplasmic reticulum Ca<sup>2+</sup> content and systolic Ca<sup>2+</sup> in cardiac hypertrophy</article-title>. <source>Cardiovasc Res</source>
<volume>62</volume>: <fpage>538</fpage>â<lpage>547</lpage>
<pub-id pub-id-type="pmid">15158146</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0019">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0019">
<string-name>
<surname>Dibb</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Eisner</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Trafford</surname>
<given-names>AW</given-names>
</string-name> (<year>2007</year>) <article-title>Regulation of systolic [Ca<sup>2+</sup>]<sub>i</sub> and cellular Ca<sup>2+</sup> flux balance in rat ventricular myocytes by SR Ca<sup>2+</sup>, Lâtype Ca<sup>2+</sup> current and diastolic [Ca<sup>2+</sup>]<sub>i</sub>
</article-title>. <source>J Physiol</source>
<volume>585</volume>(<issue>Pt 2</issue>): <fpage>579</fpage>â<lpage>592</lpage>
<pub-id pub-id-type="pmid">17932152</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0020">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0020">
<string-name>
<surname>Kimura</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kawamura</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Itoh</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Mizusawa</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ding</surname>
<given-names>WG</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ohno</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Makiyama</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Miyamoto</surname>
<given-names>A</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2012</year>) <article-title>Phenotype variations in patients carrying KCNJ2 mutations</article-title>. <source>Circ Cardiovasc Genet</source>
<volume>5</volume>: <fpage>344</fpage>â<lpage>353</lpage>
<pub-id pub-id-type="pmid">22589293</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0021">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0021">
<string-name>
<surname>Lahat</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Pras</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Olender</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Avidan</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>BenâAsher</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Man</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>LevyâNissenbaum</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Khoury</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lorber</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Goldman</surname>
<given-names>B</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2001</year>) <article-title>A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamineâinduced polymorphic ventricular tachycardia in Bedouin families from Israel</article-title>. <source>Am J Hum Genet</source>
<volume>69</volume>: <fpage>1378</fpage>â<lpage>1384</lpage>
<pub-id pub-id-type="pmid">11704930</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0022">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0022">
<string-name>
<surname>Laitinen</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Piippo</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Swan</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Devaney</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Brahmbhatt</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Donarum</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Marino</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tiso</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Viitasalo</surname>
<given-names>M</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2001</year>) <article-title>Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia</article-title>. <source>Circulation</source>
<volume>103</volume>: <fpage>485</fpage>â<lpage>490</lpage>
<pub-id pub-id-type="pmid">11157710</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0023">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0023">
<string-name>
<surname>Leenhardt</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Denjoy</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Guicheney</surname>
<given-names>P</given-names>
</string-name> (<year>2012</year>) <article-title>Catecholaminergic polymorphic ventricular tachycardia</article-title>. <source>Circ Arrhythm Electrophysiol</source>
<volume>5</volume>: <fpage>1044</fpage>â<lpage>1052</lpage>
<pub-id pub-id-type="pmid">23022705</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0024">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0024">
<string-name>
<surname>Liu</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Denegri</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ruan</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>AvelinoâCruz</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Perissi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Negri</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Napolitano</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Coetzee</surname>
<given-names>WA</given-names>
</string-name>, <string-name>
<surname>Boyden</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Priori</surname>
<given-names>SG</given-names>
</string-name> (<year>2011</year>) <article-title>Flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity</article-title>. <source>Circ Res</source>
<volume>109</volume>: <fpage>291</fpage>â<lpage>295</lpage>
<pub-id pub-id-type="pmid">21680895</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0025">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0025">
<string-name>
<surname>Makita</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Yagihara</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Crotti</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>CN</given-names>
</string-name>, <string-name>
<surname>Beckmann</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Roh</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Shigemizu</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Lichtner</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Ishikawa</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Aiba</surname>
<given-names>T</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2014</year>) <article-title>Novel calmodulin mutations associated with congenital arrhythmia susceptibility</article-title>. <source>Circ Cardiovasc Genet</source>
<volume>7</volume>: <fpage>466</fpage>â<lpage>474</lpage>
<pub-id pub-id-type="pmid">24917665</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0026">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0026">
<string-name>
<surname>Moon</surname>
<given-names>YâA</given-names>
</string-name>, <string-name>
<surname>Horton</surname>
<given-names>JD</given-names>
</string-name> (<year>2003</year>) <article-title>Identification of two mammalian reductases involved in the twoâcarbon fatty acyl elongation cascade</article-title>. <source>J Biol Chem</source>
<volume>278</volume>: <fpage>7335</fpage>â<lpage>7343</lpage>
<pub-id pub-id-type="pmid">12482854</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0027">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0027">
<string-name>
<surname>MÃ¼ller</surname>
<given-names>FJ</given-names>
</string-name>, <string-name>
<surname>Schuldt</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Williams</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Mason</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Altun</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Papapetrou</surname>
<given-names>EP</given-names>
</string-name>, <string-name>
<surname>Danner</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Goldmann</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Herbst</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Schmidt</surname>
<given-names>NO</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2011</year>) <article-title>A bioinformatic assay for pluripotency in human cells</article-title>. <source>Nat Methods</source>
<volume>8</volume>: <fpage>315</fpage>â<lpage>317</lpage>
<pub-id pub-id-type="pmid">21378979</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0028">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0028">
<string-name>
<surname>Ng</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Davis</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Stanley</surname>
<given-names>EG</given-names>
</string-name>, <string-name>
<surname>Elefanty</surname>
<given-names>AG</given-names>
</string-name> (<year>2008</year>) <article-title>A protocol describing the use of a recombinant proteinâbased, animal productâfree medium (APEL) for human embryonic stem cell differentiation as spin embryoid bodies</article-title>. <source>Nat Protoc</source>
<volume>3</volume>: <fpage>768</fpage>â<lpage>776</lpage>
<pub-id pub-id-type="pmid">18451785</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0029">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0029">
<string-name>
<surname>Nyegaard</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Overgaard</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>SÃ¸ndergaard</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Vranas</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Behr</surname>
<given-names>ER</given-names>
</string-name>, <string-name>
<surname>Hildebrandt</surname>
<given-names>LL</given-names>
</string-name>, <string-name>
<surname>Lund</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hedley</surname>
<given-names>PL</given-names>
</string-name>, <string-name>
<surname>Camm</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Wettrell</surname>
<given-names>G</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2012</year>) <article-title>Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death</article-title>. <source>Am J Hum Genet</source>
<volume>91</volume>: <fpage>703</fpage>â<lpage>712</lpage>
<pub-id pub-id-type="pmid">23040497</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0030">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0030">
<string-name>
<surname>Obeyesekere</surname>
<given-names>MN</given-names>
</string-name>, <string-name>
<surname>Klein</surname>
<given-names>GJ</given-names>
</string-name>, <string-name>
<surname>Modi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>LeongâSit</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Gula</surname>
<given-names>LJ</given-names>
</string-name>, <string-name>
<surname>Yee</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Skanes</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Krahn</surname>
<given-names>AD</given-names>
</string-name> (<year>2011</year>) <article-title>How to perform and interpret provocative testing for the diagnosis of Brugada syndrome, longâQT syndrome, and catecholaminergic polymorphic ventricular tachycardia</article-title>. <source>Circ Arrhythm Electrophysiol</source>
<volume>4</volume>: <fpage>958</fpage>â<lpage>964</lpage>
<pub-id pub-id-type="pmid">22203660</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0031">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0031">
<string-name>
<surname>Postma</surname>
<given-names>AV</given-names>
</string-name>, <string-name>
<surname>Denjoy</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Hoorntje</surname>
<given-names>TM</given-names>
</string-name>, <string-name>
<surname>Lupoglazoff</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Da Costa</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sebillon</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Mannens</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Wilde</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Guicheney</surname>
<given-names>P</given-names>
</string-name> (<year>2002</year>) <article-title>Absence of calsequestrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachycardia</article-title>. <source>Circ Res</source>
<volume>91</volume>: <fpage>e21</fpage>â<lpage>e26</lpage>.<pub-id pub-id-type="pmid">12386154</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0032">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0032">
<string-name>
<surname>Priori</surname>
<given-names>SG</given-names>
</string-name>, <string-name>
<surname>Napolitano</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Tiso</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Memmi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Vignati</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Bloise</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Sorrentino</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Danieli</surname>
<given-names>GA</given-names>
</string-name> (<year>2001</year>) <article-title>Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia</article-title>. <source>Circulation</source>
<volume>103</volume>: <fpage>196</fpage>â<lpage>200</lpage>
<pub-id pub-id-type="pmid">11208676</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0033">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0033">
<string-name>
<surname>Reed</surname>
<given-names>GJ</given-names>
</string-name>, <string-name>
<surname>Boczek</surname>
<given-names>NJ</given-names>
</string-name>, <string-name>
<surname>Etheridge</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Ackerman</surname>
<given-names>MJ</given-names>
</string-name> (<year>2015</year>) <article-title>CALM3 mutationÂ associated with long QT syndrome</article-title>. <source>Heart Rhythm</source>
<volume>12</volume>: <fpage>419</fpage>â<lpage>422</lpage>
<pub-id pub-id-type="pmid">25460178</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0034">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0034">
<string-name>
<surname>RouxâBuisson</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Cacheux</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>FourestâLieuvin</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Fauconnier</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Brocard</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Denjoy</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Durand</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Guicheney</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Kyndt</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Leenhardt</surname>
<given-names>A</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2012</year>) <article-title>Absence of triadin, a protein of the calcium release complex, is responsible for cardiac arrhythmia with sudden death in human</article-title>. <source>Hum Mol Genet</source>
<volume>21</volume>: <fpage>2759</fpage>â<lpage>2767</lpage>
<pub-id pub-id-type="pmid">22422768</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0035">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0035">
<string-name>
<surname>Ruknudin</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Wei</surname>
<given-names>SâK</given-names>
</string-name>, <string-name>
<surname>Haigney</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Lederer</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Schulze</surname>
<given-names>DH</given-names>
</string-name> (<year>2007</year>) <article-title>Phosphorylation and other conundrums of Na/Ca exchanger, NCX1</article-title>. <source>Ann N Y Acad Sci</source>
<volume>1099</volume>: <fpage>103</fpage>â<lpage>118</lpage>
<pub-id pub-id-type="pmid">17446449</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0036">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0036">
<string-name>
<surname>Schwartz</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Ackerman</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>George</surname>
<given-names>AL</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Wilde</surname>
<given-names>AA</given-names>
</string-name> (<year>2013</year>) <article-title>Impact of genetics on the clinicalÂ managementÂ of channelopathies</article-title>. <source>J Am Coll Cardiol</source>
<volume>62</volume>: <fpage>169</fpage>â<lpage>180</lpage>
<pub-id pub-id-type="pmid">23684683</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0037">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0037">
<string-name>
<surname>Stammers</surname>
<given-names>AN</given-names>
</string-name>, <string-name>
<surname>Susser</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Hamm</surname>
<given-names>NC</given-names>
</string-name>, <string-name>
<surname>Hlynsky</surname>
<given-names>MW</given-names>
</string-name>, <string-name>
<surname>Kimber</surname>
<given-names>DE</given-names>
</string-name>, <string-name>
<surname>Kehler</surname>
<given-names>DS</given-names>
</string-name>, <string-name>
<surname>Duhamel</surname>
<given-names>TA</given-names>
</string-name> (<year>2015</year>) <article-title>The regulation of sarco(endo)plasmic reticulum calciumâATPases (SERCA)</article-title>. <source>Can J Physiol Pharmacol</source>
<volume>93</volume>: <fpage>843</fpage>â<lpage>854</lpage>
<pub-id pub-id-type="pmid">25730320</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0038">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0038">
<string-name>
<surname>Takahashi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Tanabe</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ohnuki</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Narita</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ichisaka</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Tomoda</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Yamanaka</surname>
<given-names>S</given-names>
</string-name> (<year>2007</year>) <article-title>Induction of pluripotent stem cells from adult human fibroblasts by defined factors</article-title>. <source>Cell</source>
<volume>131</volume>: <fpage>861</fpage>â<lpage>872</lpage>
<pub-id pub-id-type="pmid">18035408</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0039">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0039">
<string-name>
<surname>Tester</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Ackerman</surname>
<given-names>MJ</given-names>
</string-name> (<year>2006</year>) <article-title>Postmortem long QT syndrome genetic testing for sudden unexplained death in the young</article-title>. <source>J Am Coll Cardiol</source>
<volume>49</volume>: <fpage>247</fpage>â<lpage>249</lpage>
<pub-id pub-id-type="pmid">17222737</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0040">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0040">
<string-name>
<surname>Verkerk</surname>
<given-names>AO</given-names>
</string-name>, <string-name>
<surname>van Borren</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>van Ginneken</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Wilders</surname>
<given-names>R</given-names>
</string-name> (<year>2015</year>) <article-title>Ca<sup>2+</sup> cycling properties are conserved despite bradycardic effects of heart failure in sinoatrial node cells</article-title>. <source>Front Physiol</source>
<volume>6</volume>: <fpage>18</fpage>
<pub-id pub-id-type="pmid">25698973</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0041">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0041">
<string-name>
<surname>Wang</surname>
<given-names>ZG</given-names>
</string-name>, <string-name>
<surname>Pelletier</surname>
<given-names>LC</given-names>
</string-name>, <string-name>
<surname>Talajic</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Nattel</surname>
<given-names>S</given-names>
</string-name> (<year>1990</year>) <article-title>Effects of flecainide and quinidine on human atrial action potentials. Role of rateâdependence and comparison with guinea pig, rabbit and dog tissues</article-title>. <source>Circulation</source>
<volume>82</volume>: <fpage>274</fpage>â<lpage>283</lpage>
<pub-id pub-id-type="pmid">2114235</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0042">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0042">
<string-name>
<surname>Watanabe</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Chopra</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Laver</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Hwang</surname>
<given-names>HS</given-names>
</string-name>, <string-name>
<surname>Davies</surname>
<given-names>SS</given-names>
</string-name>, <string-name>
<surname>Roach</surname>
<given-names>DE</given-names>
</string-name>, <string-name>
<surname>Duff</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Roden</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Wilde</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Knollmann</surname>
<given-names>BC</given-names>
</string-name> (<year>2009</year>) <article-title>Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans</article-title>. <source>Nat Med</source>
<volume>15</volume>: <fpage>380</fpage>â<lpage>383</lpage>
<pub-id pub-id-type="pmid">19330009</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0043">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0043">
<string-name>
<surname>van der Werf</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kannankeril</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Sacher</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Krahn</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Viskin</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Leenhardt</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Shimizu</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Sumitomo</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Fish</surname>
<given-names>FA</given-names>
</string-name>, <string-name>
<surname>Bhuiyan</surname>
<given-names>ZA</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2011</year>) <article-title>Flecainide therapy reduces exerciseâinduced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia</article-title>. <source>J Am Coll Cardiol</source>
<volume>57</volume>: <fpage>2244</fpage>â<lpage>2254</lpage>
<pub-id pub-id-type="pmid">21616285</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0044">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0044">
<string-name>
<surname>Wilde</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Behr</surname>
<given-names>ER</given-names>
</string-name> (<year>2013</year>) <article-title>Genetic testing for inherited cardiac disease</article-title>. <source>Nat Rev Cardiol</source>
<volume>10</volume>: <fpage>571</fpage>â<lpage>583</lpage>
<pub-id pub-id-type="pmid">23900354</pub-id></mixed-citation>
      </ref>
      <ref id="emmm201505719-bib-0045">
        <mixed-citation publication-type="journal" id="emmm201505719-cit-0045">
<string-name>
<surname>Zhang</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>D'Aniello</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Verkerk</surname>
<given-names>AO</given-names>
</string-name>, <string-name>
<surname>Wrobel</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Frank</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Wardâvan Oostwaard</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Piccini</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Freund</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Rao</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Seebohm</surname>
<given-names>G</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2014</year>) <article-title>Recessive cardiac phenotypes in induced pluripotent stem cell models of Jervell and LangeâNielsen syndrome: disease mechanisms and pharmacological rescue</article-title>. <source>PNAS</source>
<volume>111</volume>: <fpage>E5383</fpage>â<lpage>E5392</lpage>
<pub-id pub-id-type="pmid">25453094</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>